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Abstract 
THE EFFECT OF CLAs ON THE EXPRESSION OF PKC ISOFORMS AND 
CELL VIABILITY IN BREAST CANCER CELL LINES  
Rosemary H Crabb-Wyke 
 
Breast tumours make up 15% of the total cancer burden in the UK and around 8% of 
the total number of cancer related deaths. Protein kinase C (PKC) isoforms have 
been shown to be strongly modulated in many androgen sensitive tumour cell lines. 
Increased expression of some PKC isoforms has also been linked to immortality in 
many cancer cell lines. Conjugated linoleic acids (CLAs) are naturally occurring 
positional and geometric isomers of the fatty acid linoleic acid (LA). CLAs have 
been shown to reduce growth and increase apoptosis in breast cancer cells, and to 
alter their PKC expression both in animal models and in various human cell lines. 
      We investigated the effect of CLA on the oestrogen sensitive MCF-7 cell 
line, and the oestrogen insensitive MDA-MB-231 cell line for 24 hours at two 
different concentrations of CLA (25µM and 50µM, optimum concentrations, 
previously shown in our lab). We measured the variations of three PKC isoforms (α, 
δ, and ι) in the cytosol (inactive form) and the membrane (active form), as well as 
the mRNA expression of each in MCF-7 after 12 hours of treatment at 50µM 
concentrations. The activation of PKC was measured by Western Blot analysis, 
using PKC isoform specific antibodies and β-actin, or Claudin-3 as the 
housekeeping protein. Results indicate that the CLA isoforms used (the 911, 1012 
and a 50/50 mix of the two) cause a decrease in cell viability in both cell lines.  
It was observed that the activation of PKC α was decreased in MCF-7 cells, 
compared to the control, while the activation of PKC δ and ι was increased. In the 
MDA-MB-231 cell line PKC ι activation was decreased at both concentrations, 
while PKC α and δ activation showed no particular pattern. mRNA expression of 
PKC α and ι was generally decreased after treatment with 50µM of CLA, while PKC 
δ mRNA expression increased. These effects are similar (but not identical) to the 
ones seen in prostate cancer cell lines (LNCaP and PC3), which have been 
previously reported by our lab. 
It appears that CLA supplementation influences PKC isoform mRNA 
expression and protein activation in breast cancer cells. While the mRNA expression 
occurs in a pattern which appears to fit with that found in previous research the 
protein activation does not follow the trends suggested by work in other cell lines. It 
appears that the expression and activation of PKC isoforms are not just influenced 
by the interactions between CLA isoforms and the PKC genes in breast cancer cells.  
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 2 
1. Introduction 
1.1 Breast Cancer 
1.1.1 Cancer and the cell cycle. 
1.1.1.1 Cancer. 
Cancer is generally described as malignant neoplasia, resulting in “an abnormal mass of 
tissue, the growth of which exceeds and is uncoordinated with that of the normal tissues, 
and persists in the same excessive manner after cessation of the stimulus which evoked 
the change." (Willis, 1952). Breast cancer can be defined as a malignant neoplasm, 
centered in the mammary tissue. 
 
1.1.1.2 The Cell Cycle. 
The cell cycle (Figure 1.1), sometimes called the cell-division cycle, may be described as 
a sequence of events leading to the replication of an eukaryotic cell. It is generally divided 
into two separate “phases”, Interphase, and M-Phase. Interphase can be described as the 
period in which the cell duplicates its DNA and organelles, and increases in size prior to 
division. M-Phase is the point at which the cell actually splits into two separate “daughter 
cells”. Interphase may be further subdivided into three distinct phases known as, G1, S 
and G2. Cells which have stopped dividing for any length of time are referred to as being 
Quiescent, or sometimes as being in G0 Phase.  
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Figure 1.1 A Diagrammatic representation of the Cell Cycle. 
  
G1 Phase may be defined as the part of the cell cycle during which the cell processes prior 
to DNA replication occur. These processes include the increased cellular production of 
the various enzymes required for the replication of the cell. 
 
S Phase is the period during which the DNA of the cell is fully replicated, and histone 
production is increased. This phase is often aberrant in cancer cells, with DNA not being 
fully replicated.  
 
G2 Phase is the point in the cell cycle in which microtubules and other structural proteins 
are replicated to allow two fully functioning cells to be created after M-Phase. 
  
1.1.2 Breast Cancer Incidence and Patient Survival. 
Breast cancer has a total incidence of 15%, the highest of any cancer type in the UK 
(Cancer Research UK, 2003), despite its relative rarity in males (294 new cases of male 
breast carcinoma were detected in 2001, compared with 40786 new cases in women). 
Breast cancer is responsible for around 8% of the total number of deaths from cancer 
every year (Cancer Research UK, 2007). Given the high incidence, this figure is relatively 
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low due to the increased understanding of the disease by healthcare professionals and a 
number of effective treatments available. However the disease may become resistant to 
the currently available treatments, and when this occurs any remaining treatment is mostly 
palliative.  
 
1.1.3 Risk Factors for Developing Breast Cancer. 
There are a number of risk factors, both biological and environmental, associated with the 
development of breast cancer which may be used in determining individual risk, these 
include the reproductive history of the patient, a family history of the disease, their diet, 
their bodyweight and physical activity as well as class status and socioeconomic factors. 
In developed countries around three quarters of breast cancer cases are observed in 
women with no family history of the disease, while only one quarter appear in women 
with a genetic predisposition (Key et al. 2001). Hereditary risk factors, observed in the 
incidence of cancer clustering within the immediate family, are typified by either the 
presence of one of 5 known high risk germline mutations (BRCA1, BRCA2, ATM, PTEN 
and p53), or by a large number of lesser polymorphisms (different phenotypes occurring 
within a population). The high risk mutations themselves account for only around 5% of 
the worldwide total of breast cancer, with the lesser polymorphisms contributing to 
another 20% (Key et al. 2001, Peto et al. 1999); statistics based on non selective, 
population based studies. 
 
1.1.4 High Risk Breast Cancer Mutations. 
The high risk germline mutations BRCA1 and BRCA2 are known to be responsible for 
breast and ovarian cancers (Peto et al. 1999). Another gene, Rap80, which appears to be 
required for normal copies of BRCA1 to fulfil their role in DNA repair is currently being 
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investigated (Wang et al. 2007). ATM (ataxia telangiectasia mutated protein kinase) 
mutations play a role in the inability of the cell to sense and repair double stranded DNA 
breaks (Prokopcova et al. 2006). Mutations of the tumour suppressor gene PTEN are 
frequent, and known to be involved in Cowden disease, a condition of which breast cancer 
is a major feature, as well as other heritable syndromes (Eng, 2003). Mutations of the p53 
gene, which plays a vital role in repairing DNA damage, and activation programmed cell 
death, predispose the patient to early onset breast cancer, as well as a spectrum of other 
cancers. In particular p53 mutations have been linked to Li-Fraumeni syndrome, a 
multiple cancer syndrome causing many cancers of childhood (Chompret et al. 2000). A 
common feature of these high risk polymorphisms is that they all appear to play a role in 
the inability of a cell to repair double stranded DNA breaks. 
 
1.1.5 Lower Risk Breast Cancer Mutations. 
Research into the cumulative effects of lower risk polymorphisms is still at an early stage 
(Key et al. 2001). Meta analysis of 46 published studies examining the effects of 18 
polymorphisms showed only one allele which consistently appeared to have a functional 
importance (Dunning et al. 1999), proving the need for further work in this area. Recently 
however four of the lower risk polymorphisms have been positively identified, FGFR2, 
TNRC9, MAP3K1 and LSP1 (Easton et al. 2007). With the exception of LSP1, which 
regulates nutrophil motility, the other low risk polymorphisms are known to all play roles 
in the regulation of the cell cycle, although they act in very different ways. 
 
1.1.6 Environmental (Non Genetic) Risk Factors for Developing Breast Cancer. 
The environmental risk factors, which make up the larger number of cases, are many and 
varied. Currently there is considerable interest in the effects of endogenous hormones on 
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the chances of an individual developing breast cancer. In fact, naturally occurring steroid 
hormones, especially isoforms of oestrogen, are known to influence the normal growth of 
breast tissue, but they have also been implicated in the transformed growth of breast 
cancers. In western countries, endogenous hormones are usually found in three forms, as 
the oral contraceptive pill, in various fertility drugs and as hormone replacement therapy 
(HRT). Due to the prevalence of these medicines, their safety (or lack thereof) has 
become a matter of much public interest.  
 
HRT is usually used to alleviate the more unpleasant effects of the menopause in women 
over 55, although it may also be administered to those who suffer from an early 
menopause. In a reanalysis of prospective studies on endogenous sex hormones and breast 
cancer, by the endogenous hormones and breast cancer collaborative group, it was shown 
that women with non-inherited breast cancer have, in general, a higher serum 
concentration of sex hormones (included in the study were esterone, testosterone and 
estradiol) than healthy postmenopausal subjects (Key et al. 2002) This correlation across 
nine separate studies is highly statistically significant. Long-term use of HRT has also 
been shown to increase nodularity of the breast, as well as the number of fibroadenomas 
and cysts. Moreover, if the breast already contains established lesions, HRT has been 
shown to increase the growth rate of these. Breast density in healthy women going 
through the menopause decreases and studies examining mammograms (which provide 
the best estimate of breast density) show considerable variation in breast density between 
women of the same age in industrialised countries. Women with higher breast density are 
more likely to develop breast cancer according to a large number of studies. Indeed, 
according to White, in a news article for the Journal of the National Cancer Institute in 
2000 this likelihood is of the order of four to six times greater than women with lower 
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breast densities. White also observes that the only risk factors which have been shown to 
increase cancer likelihood more are age and mutations of the BRCA1 and 2 genes (White, 
2000). The role which diet plays in determining breast density is controversial. This is 
partially because of the interest which genetic and hormonal factors have excited among 
the research community, leading to greater exploration, at the expense of research into 
nutritional causes. It may also be because meta-analysis performed on the data available 
from both interventional and epidemiological studies fails to support the prevailing 
hypothesis that increased fat intake leads to increased breast density and higher cancer 
risk (Hanf and Gonder, 2005). Meta analyses of case control studies have shown that there 
is a significant and positive association between high saturated fat in the diet and the 
development of breast cancer (Howe et al. 1990).  
 
1.1.7 Oestrogen and Breast Cancer. 
Oestrogen is a known promoter of growth and survival (although it is also implicated in 
the regulation of transport across the epithelia of the reproductive tract) in some forms of 
breast cancer, binding to the oestrogen receptors (ER’s) which, in post-menopausal 
women, are observed in approximately 75% of breast tumours (Cancer Research UK, 
2003). It is the highly proliferative response of ER positive tumours to oestrogen which is 
the basis for anti-oestrogen therapies to treat breast cancer. In fact, the selective oestrogen 
receptor modulator Tamoxifen is the current treatment of choice for tumours exhibiting 
ER’s: in the presence of oestrogen, it binds competitively to the receptors, thus preventing 
the mitogenic effect of oestrogen. Interestingly, in cultured MCF-7 cells, when oestrogen 
is absent, Tamoxifen exhibits an agonistic effect (Sporn et al. 2001). 
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1.1.8 Oestrogen Receptors and Cell Processes. 
It has been shown that ER’s, both nuclear and membrane bound, promote the up 
regulation of genes promoting long term cell survival, the most notable example of which 
being Bcl2 (Pedram et al. 2006). ER’s are also found bound to mitochondrial membranes, 
and it is postulated that, when activated, they have an impact on the function of the 
mitochondria. The novel functions of these receptors, when in complex with Estrodiol 
(E2), are thought to aid the survival of ER positive tumours (Pedram et al. 2006). When a 
cell is “stressed” (usually by ionising radiation), the mitochondria generate ROS, which, 
being strongly oxidative, can cause damage and mutation to the structures and DNA of 
the cell. E2 has been shown to prevent ROS formation by the mitochondria in ER positive 
cancer cell lines in a dose responsive manner (Pedram et al. 2006), although E2 isoforms, 
and other steroid hormones (notably progesterone and testosterone) did not exhibit the 
same effect. 
 
Currently, there are two cell lines which are commonly used as models for ER positive 
(ER+) and ER negative (ER-) tumours. In their normal state, these are sensitive to the 
chemotoxic agents used against breast tumours although other lines have been produced 
from them which exhibit greater or lesser degrees of resistance to various chemicals.  
 
1.1.9 Fatty Acids and Breast Cancer. 
Several fatty acids (FAs) have been shown to exert different effects on breast cancer cells, 
both in culture and on induced mammary tumours in rodents. Of the FAs which appear to 
exert a beneficial effect by reducing tumour size and enhancing apoptosis in cancerous 
cells the most studied are the groups known as Omega-3s and Conjugated Linoleic acids 
(Wahle et al. 2004). 
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1.2 Linoleic Acid, Conjugated Linoleic Acid, and Their Effects on Human Health.  
1.2.1 Linoleic Acid. 
Linoleic acid (LA) is a common octadecadienoic fatty acid (also called cis-9:cis-12 
octadecadienoic acid-18:2n-6) found in a few plant species and in ruminant meat and milk 
products. LA is required in mammalian systems as the precursor of longer-chain n-6 
PUFA (Polyunsaturated fatty acids, containing more than one double bond) that in turn 
are the more immediate precursors for the biosynthesis of the C-20 eicosanoids, however, 
it is an essential fatty acid that cannot be synthesised in the human body, its dietary intake 
is therefore essential. A joint expert report, commissioned by the World Health 
Organisation, and the UN Food and Agriculture Organisation suggested that an LA intake 
of between 2-3% of total dietary energy is probably enough to prevent deficiency (Joint 
Experts. Fats and Oils in Human Nutrition, Report of a Joint Expert Consultation. WHO 
1994). LA is also known to be important in the regulation of blood pressure. In addition to 
this, replacement of saturated fat in the diet with LA has been shown to reduce the 
concentration of cholesterol in the blood, and also to reduce the risk of coronary heart 
disease. In a meta-analysis of the literature (Zock and Katan, 1998) it was concluded that 
there was no increased risk of breast, colorectal or prostate cancer with long term 
consumption of LA despite the fact that high, long term LA consumption is linked to the 
development of these cancers in various animal models. 
 
1.2.2 Modification of Linoleic Acid to Conjugated Linoleic Acid. 
LA may be modified in many ways to form various positional isomers, including 
conjugated linoleic acids, commonly known as CLA’s (see figure 1.2).  
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Figure 1.2: Structures of the two most naturally abundant CLA isoforms (t10-c12 and c9-
t11) compared with linoleic acid.  
 
CLA’s are a group of around 28 isomers of LA with conjugated double bonds at various 
positions along the fatty acid chain, the main form being the cis-9:trans-11 isomer which 
is found in the greatest abundance in ruminant fatty tissue and milk (90% of the total CLA 
content). Other isomers, of LA, including the trans-10:cis-12 form are also observed, but 
make up a much lower portion of the total CLA compliment (Jensen, 2002). The isomers 
of CLA are found naturally in some plants or formed in ruminant animals by a process of 
bio-hydrogenation, which is facilitated by microbial anaerobic fermentation. This process 
turns polyunsaturated fatty acids (PUFA) from the animal’s food, in particular plant 
matter, into saturated fats, but incomplete hydrogenation results in positional and 
geometric isomers of LA, a process which takes place in the rumen. CLA can also be 
produced commercially by partial hydrogenation of LA or by heating LA under alkaline 
conditions. The first step in the process of bio-hydrogenation is the transposition of the 
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delta 12 double bond of PUFA to form the cis-9:trans-11 isomer, often called rumenic 
acid (RA). RA can also be formed by the oxidation (introduction of a double bond) of 
trans-11vaccenic acid by delta-9 desaturase; these two routes of RA formation probably 
contribute to its natural abundance. Further isomerisation and transposition of RA leads to 
the formation of other, less abundant isomers, such as the trans-10:cis-12 isomer, which 
exhibits some anticancer effects (Parodi, 2003).  
 
1.2.3 CLA Production by Ruminants. 
The way in which ruminants are fed has a large impact on their CLA production and 
tissue concentration. It has been shown that cattle fed with oil rich corn or soy bean 
supplements have a higher concentration of CLA found in the fatty tissue than cattle fed 
on silage without any supplements (Beaulieu et al. 2002, Duckett et al. 2002). It has also 
been observed that the fatty tissue and milk of pasture fed cattle have higher 
concentrations of muscle- based CLA than feedlot (silage fed) cattle, although the pattern 
of CLA distribution in the muscle fat is very different between the pasture fed, and silage 
fed groups (Rule et al. 2002).  
 
1.2.4 CLA in Plants. 
CLA is found in some natural seed oils, including the aforementioned soy bean oil and 
pomegranate seed oil (as well as Safflower oil, from which most available over the 
counter preparations are derived), but is not present in the commercially produced 
vegetable oils used in cooking and the production of margarine products. However, the 
catalytic hydrogenation and refining process that these oils go through causes some 
limited CLA production (0.1-0.7mg/g), quantities which are negligible. It is also worth 
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noting that in making these “low fat” products much of the CLA present is removed 
(Parodi et al. 2003). 
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1.3 CLA intake in Human populations 
1.3.1 CLA Intake in Food. 
Edible oils, ruminant milk and ruminant meat products make up the main intake of CLA 
by humans, although consumption of these varies greatly within different populations. For 
example, Australian populations show estimated daily intakes of CLA in the region of 
1500mg although it is possible that this value is due to the consumption of wallaby meat, 
which contains the highest natural concentration of CLA observed so far. In comparison, 
German people have an estimated intake of between 246 and 430mg/g per day although 
the methods used to assess daily intake were different for both populations (Parodi et al. 
2003). In humans, dietary CLA can be detected in the plasma and lymph fluid and is 
known to have a positive effect on various conditions, including type II diabetes, obesity, 
arthrosclerosis and some cancers. These effects are usually protective, and appear to 
prevent, or delay the more serious problems associated with these conditions. 
 
Clinical trials involving CLA in humans have so far been limited to looking at the effects 
of the abundant c9:t11 and t10:c12 isomers on body fat and metabolism, insulin 
production and atherosclerosis. Thus far, some show results similar to those seen in rats 
and mice fed with a high concentration of CLA (Doyle et al. 2005). Results can vary 
within the population of one species, depending on age, gender, fitness and the genotype 
of the subject. However, in animal models it is much easier to control these variables, 
which may account for the differences between the human and animal studies of CLA. 
One human study which has yielded positive results looked at the effect of a mix of 
predominantly c9: t11 and t10: c12 CLA isomers had on the body weight of patients with 
type II diabetes (Belury et al. 2003). A significant number of the subjects taking a CLA 
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supplement rather than the placebo showed an inverse correlation between both body 
weight and blood plasma levels of CLA, was observed.  
 
1.3.2 CLA Absorption. 
The absorption of CLA, both in the form of Free Fatty Acids (FFAs) and Triacylglycerols 
(TAGs) has been shown to be similar in human and animal studies. The most common 
form taken by dietary supplements is that of FFAs. However, in studies carried out on 
young male Wistar rats, which are, to some extent duplicated in humans, there appears to 
be no significant advantage of one form over the other with equal absorption and 
incorporation into tissues. Similar results have been seen in studies using fish oils, with no 
significant difference in uptake between the isomers EPA and DHA (Eicosapentaenoic 
Acid, and Docosahexaenoic Acid). It is however worthy of mention that CLA in the form 
of Fatty Acid Methyl Esters (FAMEs) are less readily absorbed by the tissues (Plourde et 
al. 2006). 
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1.4 CLA and disease states  
1.4.1 Chronic Diseases. 
Chronic diseases such as diabetes, obesity, cardiovascular disease and cancer are 
becoming an important socio-economic problem in many industrialised countries. In the 
UK, this problem is exacerbated by an ageing workforce, leading to many man hours 
being lost due to these diseases. The mechanisms underlying these problems have not yet 
been fully elucidated, however it is known that those with a sedentary lifestyle and a 
calorie rich diet are at most risk of developing one or more of these problems at some 
point during their lifetime. It has been suggested that dietary fatty acids could have an 
effect in protecting the body against the onset of some of these diseases. This would 
obviously provide many benefits to society and is a large and intensive area of research. 
 
1.4.2 Obesity and Cancer Risk. 
There is a strong link between obesity and the risk of developing certain types of cancer, 
in particular colorectal and premenopausal breast cancer. Obesity is commonly connected 
with high saturated fat consumption, leading to a higher energy intake than energy used 
by the body. However, animal model studies have shown that increased CLA intake 
actually decreases adiposity in rats, mice, hamsters and pigs (Wang and Jones, 2004). The 
effect of CLA on carcinogenesis has been similarly demonstrated, both in animal models 
and in vitro, although there have been no experiments proving its efficacy in humans in 
vivo (Ip et.al 1999, Song et.al 2004). 
 
1.4.3 Animal Studies on CLA Treatment and Tumour Size.  
In animal models, especially rats, mammary tumours are either induced chemically or 
human xenografts are implanted surgically and allowed to grow and spread. The diet of 
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the animals is either an unsupplemented control, or enriched with CLA or other fatty acids 
from various sources. The animals are humanely killed and the tumours surgically excised 
and compared (Dauchy et al. 2004, Belury, 2002, Kohno et al. 2004, and Kohno et al. 
2004). Animal studies show that not only did those rats fed a diet high in CLA have a 
smaller tumour weight and less metastasis, but they were also less likely to develop 
tumours in the first place. 
 
1.4.3.1 CLA in Animal Models 
It is well reported that supplementation with CLA in animal models decreases 
tumorogenisis.  It appears not only to decrease mammary tumour size and weight in 
severe combined immunodeficient mice (SCID mice) inoculated with MDA-MB-468 
cells, but also it reduces the metastatic spread of breast cancer cells to other parts of the 
body (Visonneau et.al 1997). The MDA-MB-468 cell line is synonymous with the MDA-
MB-231 cell line used throughout this research. It is likely that SCID mice inoculated 
with the MDA-MB-231 cell line would exhibit a similar decrease in tumourogenisis. Feed 
including 20% CLA enriched butter fat has been shown to down-regulate the morphologic 
maturation of mammary epithelium in female Sprague-Dawley rats after a treatment 
period of one month (Ip et.al 1999). This study showed no impact on the overall growth 
of the rats fed with the high CLA feed compared with control, but did show a less 
complex network of ductal-alveolar branching within the mammary glands. Treated rats 
had, on average a 25% lower mammary epithelial mass, than the control group, but no 
difference in the total area of the mammary fat pad. After one month feeding with the 
enriched food the rats were given a single dose of methylnitrosourea (MNU, a known 
inducer of mammary carcinogenesis) and the incidence and yield of the resultant tumours 
were measured. In this incidence the overall reduction in mammary carcinoma risk 
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decreased by 50%, and the protection conferred appeared to be long lasting as no 
additional CLA was supplied after treatment with MNU. In addition the rats were fed with 
CLA enriched butter from both naturally occurring and artificial sources, the effect of the 
different types of CLA appeared to be negligible with regards to mammary epithelial 
mass, and modulation of mammary cancer risk, although some differences were observed 
in CLA uptake into tissues. In 1997 Thompson et al. observed similar results in female 
Sprague-Dawley rats fed with a diet supplemented with 1% CLA and treated with the 
carcinogen 7,12-dimethylbenz(α)anthracene suggesting a more universal role for 
chemoprotection by CLA.  
 
1.4.4 CLA studies on Cells In Vitro. 
 In vitro studies on various cell lines, both from breast cancers and other tumour types 
support the evidence presented by animal studies. Cancer cells, most notably prostate, 
breast and colonic, incubated with various concentrations of CLA showed decreased cell 
viability, cellular proliferation and increased apoptosis (Dugram and Fernandes, 1997, 
Majumda et al. 2002, Song et al. 2004, Field and Schley, 2004, and Bocca et al. 2006). 
Moreover, leukaemia cells show evidence of CLA incorporation into the cell membrane, 
possibly leading to increased apoptosis (Agatha et al. 2004). CLA is also shown to 
differentially regulate the expression of various proto-oncogenes, including p53, p21 and 
Bcl-2 (Majumder et al. 2002). However in some animal models it has been shown to have 
no effect on carcinogenesis, and some isoforms may even act as a promoter of tumour 
growth, especially in the ApcMin mouse (Mandir and Goodlad, 2008). 
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1.4.5 Fatty Acids and Tumours, Potential Mechanisms of Action.  
The mechanism by which fatty acids act to inhibit the growth of tumour cells is, as yet, 
still unknown although it has been hypothesised that the effect occurs because the fatty 
acids interfere with components of the cell cycle controlling cell replication (although 
some authors disagree, notably Pedram et al. 2006). It is possible that the tumour cells 
slow down in the S-Phase of the cell cycle, as it appears that treatment with fish oil at 
physiologically active concentrations (5% w/w of the total fat content in the diet) in rats 
causes an increase in the time taken for DNA replication in implanted tumour cells 
(Robinson et al. 2001). The work done in this area so far suggests that this temporary cell 
cycle arrest may be caused by the activation/inactivation of key proteins, including the 
aforementioned p53, p21 cip1/waf1 and cyclins (Field and Schley, 2004). How this 
regulation is actually effected, however, remains a mystery. Other proposed mechanisms 
of action include: changes to the function and structure of the cell membranes, altering 
their affinity for protein binding, immune development, increasing oxidative stress on the 
cells and changes in gene expression (Field and Schley, 2004).  
 
1.4.6 CLA and Cell Death. 
1.4.6.1 Programmed Cell Death (Apoptosis). 
Apoptosis may be defined as a process leading to specific morphology and death in 
eukaryotic cells. The principal of apoptosis was first described in 1842 by Carl Vogt, and 
described more precisely in 1885 by William Flemming. In 1965 John Kerr described a 
process which at the time he called “Shrinkage necrosis”, in work looking at liver damage 
in rats. Kerr subsequently described a set of unique morphological changes linked to this 
form of cell death. Further research, with increasingly complex tools suggests that 
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apoptosis is the result of a carefully balanced interplay between the various cell signalling 
pathways (O’Rourke and Ellem, 2000). 
 
Apoptosis occurs when cells are undergoing programmed remodelling, for example the 
differentiation of fingers and toes during embryo development, or after catastrophic DNA 
or cellular damage caused by mutagenic chemicals or radiation, or by viral infection or 
starvation. In healthy subjects, cell proliferation and apoptosis form a careful balance, 
however, too much cell death leads to ischemic disorders, while cells gaining immortality 
leads to cancers. 
 
Apoptosis is controlled by a range of external and internal cell signals (inducers). Internal 
inducers are triggered by cellular stress, including, but not limited to starvation, extreme 
temperature fluctuations, and hypoxia. External inducers may be in the form of toxins 
(including those used as chemotherapeutic drugs), hormones, or growth factors, and 
require either internalisation, or signal transduction to effect a response.  
 
Once apoptosis has been triggered the cell goes through several distinct stages before 
being engulfed by phagocytes to ensure that no potentially harmful intracellular 
substances are released into the surrounding tissue (see Fig 1.3, page 19). In the first stage 
the apoptotic signal is transmitted throughout the cell by a series of regulatory proteins, 
which allow termination of the signal should the death of the cell no longer be required.  
The two main methods of apoptotic regulation so far discovered are transduction via 
adaptor proteins, and mitochondrial targeting. One method of direct signal transduction is 
via Tumour Necrosis Factor (TNF) receptors. The cytokine TNF is a major factor in 
apoptotic regulation in eukaryotes, and it is known to bind to two separate receptors in 
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human cells. Tumour necrosis factor receptor 1 (TNFR1) binding by TNF induces 
apoptosis, while binding to TNFR2 (tumour necrosis factor receptor 2) prevents 
apoptosis. The binding of these apoptotic regulators causes changes in the relative levels 
of the apoptotic regulatory proteins, Bcl2, Bax and Bad. 
 
Figure 1.3. The three main stages of Apoptosis, 1. Initiation, 2. Cell Shrinkage, 3. Cell 
Breaking, and Karyorrhexis. 
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 The second method also involves changes in the Bcl2/Bax/Bad balance within the cell. 
Cellular stresses decrease Bcl2, and increase Bax and Bad production, it is possible to 
measure how stressed a group of cells are by the relative amounts of these three proteins. 
Bcl2 is an inhibitor of apoptosis and is localised to the outer membrane of mitochondria, 
where it blocks caspase activation. When Bcl2 is inactivated by Bax and Bad the 
mitochondrial membrane becomes permeable, forming mitochondrial apoptosis induced 
channels, allowing cytochrome c, and other apoptotic proteins from the mitochondria to 
escape into the cytosol. This cytochrome c forms a complex with the protein apoptotic 
protease activating factor-1 (Apaf-1), which in turn bind to other Apaf-1/cytochrome c 
complexes to form structures sometimes known as “apoptosomes”. In turn the 
apoptosomes bind to caspase-9, causing activation and triggering a caspase signalling 
cascade. The caspases triggered by this process degrade structural proteins within the cell, 
leading to the characteristic shrinking and “blebbing” as the lamin and actin filiments in 
the cytoskeleton are degraded, and the cell loses integrity. Furthermore, the DNA within 
the nucleus condenses, and the nuclear membrane degrades, a process known as 
Karyorrhexis. Finally the cell breaks down further into apoptotic bodies, surrounded by a 
membrane envelope, and tagged with phagocytotic molecules (for example Phosphatidyl 
Serene) allowing digestion by phagocytes (Potten and Wilson, 2004).   
 
1.4.6.2 Cell Death and CLA Supplimentation. 
The suggestion that CLA and other n-3 fatty acids cause tumour cells to undergo necrotic 
cell death due to increased oxidative stress is based on the idea that tumour cells have 
insufficient antioxidant defence systems compared to healthy cells. During lipid 
peroxidation, the main substrates within the cell are the Polyunsaturated Fatty Acids 
(PUFAs). Therefore, reactive compounds derived from PUFAs could cause intracellular 
 22 
changes to the cell leading to necrosis. It does appear that spermatozoa enriched with 
unesterified PUFA have a higher incidence of lipid peroxidation and induction of reactive 
oxygen species (ROS) (Aitken et al. 2006). 
 
1.4.7 CLA and Cell Viability. 
In the human colorectal cancer cell line Caco-2, concentrations of CLA above 1µM had 
some effect on the viability of cells after up to 72 hours incubation (Bocca et al. 2006). 
Repeated doses of CLA also appeared to reduce the total cell viability compared to single 
doses for the same duration (74% reduction of growth for multiple doses over 72 hours, 
compared to 66% reduction of growth from a single dose) indicating a potential for 
repeated treatments leading to tumour shrinkage in animal and human models. 
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1.5 CLA and Breast Cancer 
It is interesting to note that the advice commonly given to women undergoing treatment 
for, or recovering from, breast tumours is to avoid both dairy products and red meat, 
although it is still unclear how this helps recovery and reduces the likelihood of 
recurrence. Diet, as a factor influencing breast cancer development, is currently under 
intense scrutiny, as is discovering the specific dietary components that increase or 
decrease the chances of an individual developing a tumour. These approaches could be 
significant, both from a health and an economic perspective. 
 
Different patterns of breast cancer incidence across different populations with different 
dietary habits provide the best current evidence for a diet based component in the risk of 
developing breast tumours. CLA is known to promote cell death in the weakly metastatic 
and ER+ MCF-7 cell line (>60% inhibition of growth), even at low concentrations 
(25µM) although it appears to have little or no effect on the strongly metastatic and ER- 
MDA-MB-231 line (<5% inhibition of growth) (Tanmahasamut et al. 2004). The addition 
of CLA also has a direct action on oestrogen signalling, both by decreasing ERα receptor 
expression and by suppressing the active binding of the oestrogen response element 
(EREv) to the ERα receptor. The decrease in receptor expression appears to be linked to a 
decrease in ERα mRNA, linked to a decrease in the protein itself, as confirmed by 
Western Blot analysis (Tanmahasamut et al. 2004). 
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1.6 Protein Kinase C isoforms 
1.6.1 The PKC Family. 
The protein kinase family are implicated in many intracellular signalling pathways, 
sometimes exhibiting opposing functions, including the signalling cascades, which trigger 
cell division. PKC is a subfamily of serine/threonine kinases comprising 12 known 
isoforms. These isoforms can, in turn, be split into three categories, typical PKC’s (α, βI, 
βII, and γ), novel PKC’s (δ, ε, η, θ, and µ) and atypical PKC’s (ζ, and ι/λ) based on the 
biochemical properties of each isoform. The hallmark of the activation of all the PKC 
isoforms is the translocation of the protein from the cytoplasm to the cellular membrane. 
The typical and novel isoforms of PKC are known to be dependant on the presence of 
phosphatidylserine (PS) for activation, these isoforms also require allosteric activation, 
either by diacylglycerol (DAG, a lipid-derived second messenger, generated in the plasma 
membrane), or by negatively charged phospholipids. The atypical PKC isoforms, 
however, require neither PS nor DAG for activation; PS is still capable of activating these 
isoforms, but it is not a necessary step in the activation process and can be replicated by 
the addition of phosphatidylethanolamine. The atypical PKCs may be regulated by 3-
phosphoinositides (PIP3, Nakanishi et al. 1993). If prolonged PKC activity is being 
observed in vitro, the extensively studied group of tumour promoters known as phorbol 
esters (2 orders of magnitude more potent than DAG) also act as activators of PKC 
(Newton AC, 1995) for recruitment to the plasma membrane. DAG exerts its effect by 
increasing the affinity between the PKC isoforms and the PS enriched areas of the cell 
membrane; this causes a conformational change which serves to remove the 
pseudosubstrate domain from the binding site, thus activating PKC (Carter, 2000). The 
typical PKCs also require calcium ions to induce maximal activation, C standing for 
calcium in PKC and the first isoforms to be differentiated was named PKC α. If no 
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calcium or DAG is present within the cell then the typical PKCs are still capable of 
interacting with the plasma membrane, but these interactions are, at best, weak and 
transitory (Steinberg, 2004). DAG is produced by the turnover of phosphatidylinositol by 
various cellular receptors, including p21, Wnt5A (via G-protein coupled receptors, also 
leading to a rise in intracellular Ca2+, Dissanayake et al. 2007), and receptors in the ras 
pathway, and upon activation by extracellular factors. Anderson and Welsh (1990) 
suggested that phospholipase C (PLC), bradykinin, isoproteranol and adenosine 3',5'-
cyclic monophosphate (cAMP) are the main ones, with PLC and bradykinin stimulating 
membrane bound phosphatidylinositol hydrolysis, and cAMP and isoproteranol acting on 
a separate, unknown source. For this reason, PKC is believed to play an important role in 
signal transduction. It was observed by Newton in 1997 that when PLC hydrolyses 
phosphatidylinositol, specifically phosphatidylinositol-4,5-bisphosphate, it produces 
intracellular inositol-1,4,5-trisphosphate in addition to DAG. It is this inositol-1,4,5-
trisphosphate which binds to intracellular IP3 receptors to cause the increase in 
intracellular Ca2+ ions which facilitate the preferential binding of typical PKC isoforms to 
the plasma membrane (Newton, 1997). 
 
1.6.2 The PKC Isoforms. 
In 1995, Ford et al. looked at differential expression of PKC isoforms in various tissue 
types of the horseshoe crab, Limulus polyphemus. These experiments appeared to suggest 
that certain isoforms are abundantly present in different cell types: this, therefore, 
suggests that a unique function is performed by each isoenzyme (Ford et al. 1995, See 
Table 1.1).  
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Table 1.1 : The PKC isoforms and their effects 
PKC 
isoform 
Effect on the cell  
PKC α Enhances cell proliferation, anti apoptotic, increased multi drug resistance 
(Leszczynski et al. 1996) 
PKC βI Increased blood vessel growth and leakage, enhances abnormal  VEGF 
signalling (Pass et al. 2001) 
PKC βII Increased blood vessel growth and leakage, transmits hypertrophic signals in 
the myocardium (Pass et al. 2001) 
PKC γ Only expressed in brain and neuronal tissues, implicated in neuronal function 
(Saito and Shirai, 2002) 
PKC δ Reduced cell growth, reduced cell motility, reduced cell morphology, pro 
apoptotic (Mischak et al. 1993) 
PKC ε Enhances cell proliferation, anti apoptotic, desensitisation to TNFα (Mischak 
et al. 1993) 
PKC η Aberrant morphology, increased tumour metastasis, anti apoptotic (Masso-
Welch et al. 2001) 
PKC µ Pro-apoptotic (Nakajima, 2006) 
PKC θ Pro-apoptotic (Nakajima, 2006) 
PKC ι Anti-apoptotic, up-regulates NF-κB and activates pathways essential for 
transformed cell growth, linked to determining cellular polarity (Lu et al. 
2001) 
PKC λ Anti-apoptotic, up-regulates NF-κB and activates pathways essential for 
transformed cell growth, linked to determining cellular polarity (Lu et al. 
2001) 
PKC ζ Anti–apoptotic and implicated in multi drug resistance (Jiang et al. 2000) 
 
For example, over expression of PKC α and ε appear to be involved in enhanced cell 
proliferation (Leszczynski et al. 1996, Mischak et al. 1993) whereas over expression of 
PKC δ causes a slowing of cell growth and a reduction of cell density, as well as 
significant changes in morphology (Mischak et al. 1993). These effects are isoform and 
cell type specific, but also appear to depend on context, with isoforms exhibiting both 
pro- and anti-apoptotic properties in response to different cellular events or insults. It has 
been postulated that the presence of multiple PKC isoforms in a single cell type is 
indicative of a unique, rather than overlapping, function assigned to each isoform (Carter, 
2000). The downstream signalling pathways of PKC are less well characterised although 
it is known that the main signal cascade activated by PKC is the MERK-ERK. PKCα has 
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been shown to activate Raf1, which is another Serine-Threonine kinase. Raf1 is also an 
activator of MERK-ERK. The activation of Raf1 by the PKCα in turn activates MRK1 
and 2 by phosphorylation and triggers the mitogen activated protein kinase (MAPK) 
cascade. Once activated, the MAPK cascade induces the transcription of genes involved 
in cell division and precipitates the cell into S-phase (Mackay and Twelves, 2003). PKC ζ 
is activated by the second messenger protein ceramide and may also be implicated, along 
with a host of other ceramide activated protein kinases (CAPKs) in cellular stress 
response pathways. Specifically PKC ζ appears to activate Jun N-terminal kinase (JNK) 
proteins, involved in cell response to cellular stress (see figure 1.4 for a diagrammatic 
representation of the PKC pathway) (Herr and Debatin, 2001). 
 
Figure 1.4 A diagrammatic view of general PKC activation and a few downstream effects 
of activated PKC.  
Key: GDP- guanosine-5'-diphosphate; GTP- guanosine-5'-triphosphate; PLC- 
Phospholipase C; PIP2- Phosphatidyl inositol-4,5-bisphosphate; IP3- inositol-1,4,5-
trisphosphate; DAG- Diacylglycerol.  
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There is also evidence that PKC signalling cascades are implicated in early and late stage 
of fertilization events, at least in mammalian egg cells, probably due to DAG production 
via oscillations in cellular Ca+ although direct evidence of this is lacking (Halet, 2004). 
 
1.6.3 PKC in Breast Cancer Cells. 
In the oestrogen positive MCF-7 breast cancer cell line, three universally expressed PKC 
isoforms have been detected, (α, δ, and ζ) as well as PKC ε and η (Basu et al. 2002, de 
Vente et al. 1995, Soh et al. 2003, Lavie et al. 1998, Kambhampati et al. 2003 and 
Masso-Welch et al. 2001). Cells over-expressing PKC α and ε are shown to proliferate at 
a higher rate than the parental cells (de Vente et al. 1995), to have an increased multi-drug 
resistance (greater expression of PKCα) and, where PKCε is over-expressed, to have a 
desensitisation to tumour necrosis factor (TNF). Nuclear localisation of PKC δ is required 
for apoptosis (DeVries et al. 2002), also cells which over-express PKC ζ are expected to 
be apoptotic (Jiang et al. 2000), while cells which over express PKC η are shown to have 
an aberrant morphology and, it is hypothesised, that PKC η is implicated in tumour 
metastasis (Masso-Welch et al. 2001) (see table 1.1, page 25, for the effects of different 
PKC isoforms).  
 
1.6.4 Structure of PKC. 
1.6.4.1 The PKC Domains. 
PKC has been shown to be a single polypeptide chain formed of two structurally distinct 
regions. The 45kDa C-terminus contains the highly conserved catalytic domain and 
shows, mostly, an α-helical conformation. On the other hand, the 20-70kDa N-terminus 
region contains the regulatory, and co-factor binding domain and a β-pleated sheet 
structure. These two domains are separated by a hinge region which, during activation of 
the enzyme, becomes proteolytically labile (Newton, 1995). In the 1980’s, the cloning of 
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the α, β, and γ PKC isoforms identified in human and bovine tissue revealed four highly 
conserved domains of the protein sequence interspersed with variable regions (Coussens 
et al. 1986). These domains are now referred to as C1-C4. The C1, C3 and C4 domains 
are found in all identified PKC isoforms, although the atypical PKCs have a slightly 
differing structure (Newton, 1995, Figure 1.5).  
 
Figure 1.5. Diagrammatic representations of the three classes of PKC isoform showing 
the various domains. 
 
Typical and Novel PKCs contain two tandem C1 domains (commonly referred to as C1a 
and C1b), while atypical PKCs only contain one which lacks the ability to bind to DAG. 
The C2 domain, which appears to confer the calcium, and acidic phospholipid binding 
properties to the molecule, is only found in the typical and novel PKC isoforms (Burns 
and Bell, 1991), although, in novel PKCs, it lacks the residues which allow it to bind to 
Ca2+ ions. All these domains have a specific function, established by mutational and 
biochemical analysis. Moreover, also found in the C2 domain, are areas for interaction 
with receptors for activated C kinase (RACK). It is believed that RACKs play a role in the 
translocation of the activated PKC from the cytosol to the plasma membrane. RACK may 
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also be important modulators of PKC activity, probably through alterations to the 
regulatory sites by phosphorylation (da Rocha et al. 2002).  
 
1.6.4.2 The C1 Domain. 
The C1 domain is prefaced by an auto inhibitory pseudo substrate sequence between 
amino acids 19 and 36 which resembles a substrate phosphorylation site, thought to be 
responsible for maintaining the isoform in its inactive state (House and Kemp, 1987). The 
C1 domain itself is a region of approximately 50 amino acids approximately 8kDa in 
weight, and contains a double cystine rich motif (in atypical PKCs, there is only a single 
one of these motifs) containing a pair of Zn2+ ions which are interleaved and integral to 
the structure (Burns and Bell, 1991). It has been shown to be the lipid binding site for 
DAG and for phorbol esters such as PMA and TPA. This was first determined by the use 
of radio-ligands (specifically [3H] phorbol 12, 13-dibutyrate) in the 1970’s (this method 
being the gold standard for determining ligand and lipid affinity in protein/membrane 
interactions) (Colon-Gonzalez and Kazanietz, 2006). C1 domains with a single repeat of 
the cystine motif, identified as: 
HX12CX2CXnCX2CX4HX2CX7C 
(C being Cystine, H being Histidine and n being either 13 or 14) 
C1 domains are also found in related proteins, including diacylglycerol kinases (DGK) 
and Protein Kinase D (PKD). This domain was originally believed to contain binding 
regions for DNA, as it is structurally similar to the zinc finger domain of various 
transcription factors. It must be noted however, that the biochemistry of this site is quite 
different and cannot bind to DNA (Newton, 1995). 
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Dries et al.  in 2007 observed that the 22nd residue of the C1 (C1a in typical PKCs) 
domain in both the typical and the novel PKC isoforms is always Tryptophan (Trp), and it 
is thought that this is the best candidate for modulating ligand dependant affinity with 
cellular membranes. The mechanism of action is believed to lie within the ability of the 
residue, (sited at the surface of the protein, along one of the two loops of the C1 domain 
known to be responsible for ligand binding), to interact with the membrane, due to the 
indole ring which makes up the functional group of the amino acid. The experiment done 
by Dries et al show that mutation of the C1b domain of the typical PKCs, PKC βI and II 
from a Tyrosine (Tyr) to a Trp residue causes a 31 fold increase in the ability of the 
isoforms to bind to lipid vesicles containing 5 mol % DAG and 30 mol % 
Phosphyltidylserine (PS). It is noteworthy, however, that neither the mutant, nor the wild 
type isoforms bound to the vesicles which contained 0 mol % DAG and 30 mol % of PS, 
showing that the presence of 1,2-DAG is crucial to the membrane binding mechanism of 
the isoform. They use this fact to suggest that the C1 domain is a potential target for 
isoform specific compounds, designed to mimic the structure of DAG. A ring of positive 
charges, at the middle of the C1 domain, is believed to facilitate membrane binding, 
possible by interaction with the PS, or other lipids with anionic properties (Hurley and 
Meyer, 2001). The DAG sensitive C1 domain has also been shown to have a role in the 
redistribution of PKC isoforms in response to ATP competitive inhibitors. Takahashi and 
Namiki showed that the endogenous isoforms PKC α and δ are translocated from the 
membrane to the cytoplasm of HeLa cells when the cells are treated with the ATP-
competitive inhibitor GF 109203X. Translocation occurs at a concentration of 1µM for 
PKC δ (preferentially to the perinuclear membrane region), and a slightly higher 
concentration (10µM) for PKC α (causing translocation mainly to the endothelial, and 
plasma membranes).  PKC ζ translocation remained unaffected by any concentration of 
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GF 109203X. Other known ATP-competitive inhibitors, including the antiproliferative 
Staurosporine have also been shown to induce PKC α, and δ translocation. 
 
1.6.4.3 The C2 Domain. 
The C2 domain contains a 70-residue β-pleated sheet structure which, with loops at the N 
and C termini, and five aspartate residues (different on the non Ca2+ binding novel PKCs), 
forms the recognition site for Ca2+. The negatively charged (acidic) phospholipids are 
believed to be bound by aromatic amino acids and Ca2+ increases the enzyme affinity for 
the phospholipids (missing in novel PKCs), possibly by causing a conformational change 
in the N terminus region (Newton, 1995). The engagement of the C1 and C2 domains 
with the plasma membrane is thought to lead to the conformational change responsible for 
expelling the pseudosubstrate domain from the substrate binding site, leading to the 
activation of PKC as an enzyme capable of phosphorylating substrates bound to the 
membrane (Steinberg, 2004).  
 
1.6.4.4 The C3 and C4 Domains. 
The C3 and C4 domains are implicated in the binding of ATP and of the enzyme substrate 
MgATP, a property which it shares with the archetypal kinase, protein kinase A (PKA) 
(Newton, 1995). The C3 and 4 domains are also the target of the ATP-competitive 
inhibitors mentioned previously. Although this model provides an adequate explanation of 
how the enzyme is activated, and anchored to the membrane (by bringing it into closer 
proximity with its various membrane bound substrates, peptides with sequences similar to 
the pseudosubstrate domain of the enzyme), it fails to show how PKC isoforms exert their 
activity on non-membrane bound proteins. 
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1.6.5 Enzymology of PKC 
The structure of the catalytic core of the archetypal PKC is homologous with protein 
kinase A (PKA), which uses ATP atoms bound to Mg2+ (MgATP). Typical PKCs and 
PKA are thought to show a 40% homology in the structure of their catalytic domain. It is 
the substrate binding cavity of PKC however which, unlike PKA exhibits a cluster of 
acidic residues which appear to hold the pseudosubstrate in place (Newton, 1995). PKA is 
highly stereospecific and phosphorylates serine and threonine residues with high 
specificity, requiring specific charges at the site of phosphorylation (Newton, 1995). 
However, PKC has apparently no requirement for positively charged residues at the 
phosphorylation site (Newton, 1995, Kishimoto et al. 1985). PKC phosphorylates L-
amino acids as well as D-serine and D-threonine: however, the phosphorylation of the D-
residues is a whole order of magnitude smaller than for an L-peptide. On the other hand, 
the Km (the Michaelis constant, which assumes that the enzyme and substrate are in 
equilibrium with the complex, and that the complex dissociates to leave the free enzyme, 
and its product.) value for PKC when one D-residue is introduced is close to the 
biological norm, and if two or more D-residues are substituted the Km increases (Eller et 
al. 1993). In addition to this, PKC isoforms also exhibits ATPase activity, and, in the 
presence of excess ADP, they will exhibit phosphatase activity as well (Newton, 1995). 
 
1.6.6 PKC isoforms. 
1.6.6.1 PKC α 
PKC α has been characterised as being generally anti-apoptotic after radiation induced 
damage to the cell. However, the persistent translocation of the 82kD PKC α isoform to 
the cellular membrane has been implicated in apoptosis in LNCaP (androgen sensitive 
prostate cancer cells) (Powell et al. 1996). This translocation appears to be driven by 
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ATP-induced Ca+ influx into the cells, as opposed to Ca+ from intracellular stores (Marin-
Vicente et al. 2005). Other evidence suggests that all PKC isoforms translocate to the 
membrane in the same manner. MCF-7 cells, over-expressing PKC α, show a higher 
growth rate and more cells in S-phase at any time point (Ways et al. 1996). These cells 
also exhibit anchorage independent proliferation and a loss of ER, possibly leading to 
decreased tamoxifen sensitivity as well as multi-drug resistance. Potentially, the inhibition 
of PKC α will, in cells which over-express the isoform, trigger the signalling cascade 
leading to apoptosis and cell death. However, in cell lines under-expressing PKC α (for 
example in colon cancer), the isoform has the potential to act either as a growth inhibitor, 
or as a promoter of apoptosis, although the activation of other PKC isoforms, especially 
PKC δ, may be required (da Rocha et al. 2002). 
 
PKC α is also a known modulator of the Bax (sometimes referred to as Bax ζ) and Bcl2 
genes. Bax is a part of the Bcl2 gene family which are known for their effects on 
apoptosis, both pro- and anti-apoptotic via the mitochondrial pathway.  
Bax and Bcl2 form a heterodimer which functions as an activator of apoptosis. It is 
reported that the heterodimeric protein associates with the mitochondria and activates 
voltage-dependant anion channels, causing the release of cytochrome c (NCBI Entrez 
Gene Database, Herr and Debatin, 2001). Members of the Bcl family can act in an 
agonistic or antagonistic manner in relation to each other, directly influencing the 
response of the cell to cellular stress. It is interesting to note that increased levels of Bax 
appear to increase the susceptibility of tumours to chemotherapeutic drugs, while 
increased PKC α has quite the opposite effect. There is also some evidence that PKC α 
affects the regulation of the telomeric protection enzyme telomerase by binding to the 
telomerase associated protein 1 (TEP-1), a 300kD peptide with a structure similar to that 
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of RACK-1 (which also contains multiple WD-40 repeats in the C-terminal region). The 
telomerase is responsible for the synthesis and maintenance of the DNA at the telomeres 
(ends) of eukaryotic chromosomes. The telomere stability is essential as DNA shortening 
can affect chromosome pairing and genetic stability. The lack of enough functional 
telomerase and the resulting chromosome degradation usually leads to cell cycle arrest 
and potentially fusion of chromosomes (as seen in genetic defects such as Down 
Syndrome). However, it appears that the telomerase is over-expressed in many human 
cancers, suggesting its role in cell immortalisation (Li et al. 1998). 
 
PKC α is also implicated in cell adhesion, transformation and the control of cell volume 
as well as functioning as a regulator of the cell cycle checkpoint. Studies in PKC α 
“knockout” mice suggest that the protein also plays a role in regulating cardiac 
contractility (Braz et al. 2004). For its activation and to exert its enzymatic effects, PKC α 
requires phosphorylation at threonine 497. It may be assumed that the anti-apoptotic 
properties and actions of PKC α differ depending on where, within the cell, it is located 
(cytosol or membrane). Its effects are also a function of the cell type. This can also be 
applied to the different PKC isoforms. 
 
1.6.6.2 PKC δ. 
The 78 kD PKC δ was the first isoform discovered which did not require calcium for 
activation, hence its “novelty”. Being the first to be discovered, it is also the most widely 
researched of the novel PKC sub-family. PKC δ is usually characterised as being pro-
apoptotic based on its reaction after radiation damage to the cell, it is also known to 
enhance differentiation in a number of undifferentiated cell lines (Steinberg, 2004). 
Phorbol esters such as 12-o-tetradecanoylphorbol myristic acetate (TPA) bind with high 
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affinity to PKC δ, causing activation and cell cycle arrest even without the presence of 
DAG (Watanabe et al. 1992). However, long term exposure to phorbol esters causes a 
down regulation of PKC δ. PKC δ was the first PKC isoenzyme to be identified as a 
substrate for the group of apoptotic proteases known as interleukin-1 converting enzyme 
(ICE) like proteases, also known as the “Executioner caspases” (Basu, 2003). 
Subsequently, PKC δ was specifically identified as a substrate for caspase-3. Caspase-3 
cleaves PKC δ from its auto inhibitory regulatory domain, leading to the activation of its 
catalytic domain. In cells lacking a functional caspase-3, like MCF-7, PKC δ remains 
uncleaved, and, due to the different intercellular localisation of the full length and cleaved 
proteins, PKC δ exerts different effects (Basu, 2003). Upon activation (i.e. response to 
cellular stress such as H2O2) it has been observed that PKC δ translocates from the 
cytoplasm to the cell membrane. Moreover, it has been demonstrated that it can also 
translocate to the mitochondrial membrane (Basu, 2003), therefore initiating cellular 
apoptosis. 
 
Activation of PKC δ is believed to inhibit cell cycle progression and its down regulation 
has been linked to tumour progression. However, some studies have shown that the up-
regulation of mutant forms of PKC δ in MCF-7 causes increased tamoxifen resistance and 
decreased the number of oestrogen receptors at the cell surface both in vivo and in vitro 
(other studies ascribe similar properties to PKC α, Mackay and Twelves, 2003). This 
suggests that, in the presence of tamoxifen, the PKC δ pathway is a major alternative 
pathway for cell growth (Nabha et al. 2005). The ability of PKC δ mutant forms to 
stimulate cell growth is linked to the activation in transformed cells of the ERK/MAPK 
cascade independent of the ras pathway, especially by the constitutively active PKC δ 
mutant (Steinberg, 2004). It has also been observed that, when cells are exposed to a death 
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stimulus (either radiation or chemical), the proteolytic activation of PKC δ is increased. 
This activation correlates with an increased rate of apoptosis, which suggests a link 
between the two. 
 
There is some evidence that PKC δ can act in a lipid independent fashion if 
phosphorylated at specific tyrosine residues by the Src family Kinases (SFKs). They also 
accumulate in the cytosol of cells subjected to oxidative stress. It is, therefore, postulated 
that it may have widely differing properties to the membrane bound form as they are in a 
position to phosphorylate substrates throughout the cell (Steinberg, 2004).  
 
Finally, PKC δ is also known to regulate the co-transport of potassium, sodium and 
chloride ions across the pulmonary epithelia. 
  
1.6.6.3 PKC ι. 
PKC ι shares 72% amino acid similarity with the other atypical PKC λ and ζ, with the 
highest degree of conservation being observed in the catalytic domain. In humans, the 
tissue distribution of PKC ι (observed using Northern Blot analysis) shows the strongest 
expression in the brain and then in lungs and kidneys (Selbie et al. 1993). In addition to 
its activities as an oncogene in its own right in non small cell lung cancer (NSCLC, 
Regela et al. 2005) PKC ι is implicated in the signalling pathways of several oncogenes, 
including NF-κB, Bcr-Abl and Ras/MEK. In particular, PKC ι is a critical regulator of the 
cell survival factor NF-κB in chronic myeloid leukaemia cells, and prostate cancer cells 
(Lu et al. 2001, Win and Acevedo-Duncan, 2008). In NSCLC, it is indispensable for 
transformed, but not adherent growth both in vivo, and in vitro (Regala et al. 2005), and it 
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activates a Rac1/Pak/Mek1,2/Erk1,2 pathway responsible for transformed growth (figure 
1.6). 
 
Figure 1.6. A Diagrammatic view of the Rac1/PAK/MEK/ERK cancer pathway. Showing 
activation of RAF1 by PKC ι, leading to phosphorylation of MEK, the dissociation of the 
MEK/ERK complex, and translocation of ERK to the nuclear membrane (Eblen et al. 
2002). 
 
 
High levels of PKC ι have been shown to contribute to poor prognosis in patients with 
ovarian cancer (Eder et al. 2005), leading to speculation that it may prove to be a useful 
biomarker for aggressive ovarian carcinoma. It has also been shown to increase nicotine 
stimulated cell migration and invasion (Xu and Deng, 2006), as well as being implicated 
in colon carcinogenesis (Murray et al. 2004). This has lead to speculation that increased 
PKC ι levels may also exert similar effects in breast cancer cells.  
 
1.6.6.3.1 PKC ι and Cellular Polarity. 
It has been observed that PKC ι is involved in the polarisation of Drosophila cells: 
abnormal cellular polarity may be linked to increased chance of metastasis in cancer cells. 
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It has been observed that cancerous tissues containing high levels of PKC ι, such as lung 
carcinoma, are more likely to be metastatic than other cancers, possibly due to improper 
polarity causing the cells to fail to adhere to their neighbours. Activation of PKC isoforms 
in fertilized mammalian oocytes is concentrated around the polar body (daughter cells 
generated by asymmetrical cell division which appear to play a role in early embryo 
polarity), again suggesting a role for PKC in determining cell polarity. However, in this 
case, the specific isoforms were not distinguished (Halet, 2004). The atypical PKC 
isoforms appear to have highly specific roles in vivo in mammalian cells.  Genetic 
targeting has shown that in the early embryonic stages of mouse embryos a deficiency of 
PKC ι is fatal (Bandyopadhyay et al. 2004). However, embryos deficient in PKC ζ are 
still viable but they lack proper IL-4 and NF-κB signalling ability (Martin et al. 2002). 
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1.7 PKC and apoptosis 
As previously discussed, it is known that the PKC isoforms are intercellular signalling 
molecules and have been shown to be involved in a number of cellular processes by the 
phosphorylation of key components of various pathways, including those regulating 
cytoskeletal functions, transcription of genes and apoptosis. In particular, there are 
definite links between cellular apoptosis and the presence of the various PKC isoforms, in 
particular PKC δ, although most cells co-express different isoforms, making the PKC 
family a potential target for chemotherapeutic drugs. 
 
The three key features of tissue homeostasis are cell proliferation, differentiation and 
apoptosis. Apoptosis is the programmed death of a cell characterised by cell shrinkage, 
release of cytochrome-c from the mitochondria, and continued metabolic processes until 
the later stages. It is opposed to necrosis, which is an un-programmed death involving 
leakage of cell components and therefore inflammation of the surrounding tissues. Many 
apoptotic processes, in different cell types, appear to be mediated, to some extent, by the 
activation of the cystiene protease family known as caspases. Caspases have also been 
shown to be cleaved by PKC isoforms (however, see section 1.6.6.2 for an alternative), 
which suggests that they are acting downstream of PKC in the signalling cascade (Adayev 
et al. 2003). At least two groups of caspases have been identified, the ones initiating 
apoptosis (sometimes referred to as “initiator caspases”) and those which actually cleave 
specific substrates (for example the cytoskeletal proteins or the DNA protector protein 
ICAD), called “effector caspases”. After activation, the caspases are known to cleave their 
substrate proteins at the aspartic acid residues in the tetrapeptide recognition motif (Herr 
and Debatin, 2001). 
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Caspase-3 production can be induced by UV radiation (Matsumura et al. 2003). After 
DNA damage, the mitochondria releases, among other compounds, the cytochrome-c into 
the cytosol which triggers the activation of caspase-9 by the interaction between 
procaspase-9 and Apaf-1 (=a “caspase adaptor protein”). The caspase-9 then activates a 
number of downstream caspases, including caspase-3 (Herr and Debatin, 2001). The 
ability of caspase-3 to cause apoptosis can be reduced by over-expression of some PKC, 
in particular PKC η (Matsumura et al. 2003). 
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1.8 PKC and Cancer 
The PKC isoforms can be activated by phorbol esters (tumour promoting agents) in the 
same way as DAG. The action of phorbol esters is twice as potent as that of DAG. In fact, 
they induce conformational changes in the protein surface increasing its hydrophobicity 
and, therefore, its affinity for membrane lipid groups. However, it has been observed in 
vivo that the long-term activation of PKC by phorbol esters causes the cell to down-
regulate PKC isoform production. 
 
Elevated PKC isoform levels have been observed in many different types of tumour, 
including prostate (Song et al. 2004), breast (Soh et al. 2003, de Vente et al. 1995) and 
lung (Regala et al. 2005). They are also associated with malignant transformation of cells. 
The different isoforms are under-, or over-expressed at different stages in different cancer 
types (Mackay and Twelves, 2003). “Mislocalization” of PKC isoforms may also be 
implicated in the creation of abnormal cells, potentially by causing changes in cell 
polarity and therefore altering the cells adhesion properties (Eder et al. 2005). 
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1.9 PKC as a target for anti-cancer therapies     
1.9.1 PKC Isoform Expression in Breast Cancer.  
A study, comparing PKC expression in cancerous and normal tissues of mastectomy 
patients (9 patients), showed elevated PKC levels in the cancerous tissues compared to the 
healthy tissue. Therefore, it has been hypothesised that PKC inhibitors are strong 
candidates to be the next generation of chemotherapeutic drugs (Mackay and Twelves, 
2003). Agents targeting specific isoforms, classified according to the PKC site where they 
exert their effect, could be used to decrease cell viability, increase androgen receptors 
(linked to good prognosis in breast and prostate cancers) and increase the cytotoxicity of 
existing chemotherapeutic drugs. On the other hand, the current state of knowledge about 
the downstream signalling pathways of PKC may prove a bar to the use of PKC inhibitors 
to treat cancer. Indeed, their effects on healthy cells are likely to be diverse and 
unpredictable. Moreover, currently, there are only a small number of isoform specific 
PKC inhibitors, which therefore limits the scope of action. 
 
Some bacteria have the ability to prevent DNA damage by ionizing radiation (IR) via the 
production of superoxide anions and reactive oxygen intermediates (ROI). Moreover, 
eukaryotic cells up regulate PKC δ expression in response to DNA damage induced by IR 
(Basu, 2003, Limoli and Ward, 1993). Following IR damage, PKC δ activation appears to 
be induced by ICE-like proteases. However, no PKC δ activation has been detected in 
response to stress caused by H2O2 (Limoli and Ward, 1993). Staurosporine is a known 
antiproliferative agent, a microbial alkaloid produced by Streptomyces bacteria, with 
physical properties similar to ICE-like proteases. Staurosporine is not specific and binds 
indiscriminately to all typical and novel, but not atypical isoforms of PKC (Newton, 
1997), which causes their inhibition. However, it is this property that enabled the 
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discovery of potential isoform specific PKC inhibitors. More selective, but less potent 
than staurosporine are the calphostins, extracted from Cladosporium cladosporoides, a 
fungus. Calphostins are part of a group of chemicals known as perylenequinones. Their 
mechanism of action on PKC isoforms is twofold: competitive binding at the DAG 
binding site and covalent modification of the lipid binding regulatory domain. However, 
they also interfere with intracellular transport, inhibit cell growth and induce apoptosis in 
normal cells. Therefore, more research and structural modifications are required before 
they can be considered for trial as anticancer agents (da Rocha et al. 2002). 
 
Bryostatins, which are derived from the Bugula neritina species of marine bryozoan 
(colonial marine animals, superficially similar to corals), are a class of up to 20 
macrocyclic lactone compounds. They have been shown to have an effect in activating the 
isoforms of typical and novel PKC. However, in the presence of DAG (or, in cancer cells, 
phorbol esters) the bryostatin compounds have been shown to act as antagonists (Mackay 
and Twelves, 2003). In vivo, bryostatin treatment shows differences in PKC isoform 
expression and increases in TNF-α and IL-6, both known to decrease tumour size. In 
phase I trials, bryostatin showed some beneficial clinical effects. However, in phase II 
trials these effects could not be replicated (Mackay and Twelves, 2003).  
 
1.9.2 Development of PKC Isoform Specific Inhibitors. 
The process of trying to develop PKC isoform specific inhibitors is being investigated and 
some success has been found with agents binding to the ATP binding site. Of these 
compounds Rottlerin (Mallotoxin) which is derived from the Kamala plant (Mallotus 
philippinesis) is probably the best investigated (Way et al. 2000). Rottlerin is a compound 
 45 
which exhibits some selectivity in inhibiting PKC δ, however, more experiments are 
required to examine the extent of its usefulness. 
 
Studies in breast cancer have shown that tamoxifen, a triphenylethylene with 
antioestrogenic properties, inhibits the kinase activity of various PKC isoforms. 
Tamoxifen exerts this effect essentially in oestrogen receptor negative cells (da Rocha et 
al. 2002).  
 
A more specific approach is to design antisense oligonucleotides and peptides that will 
promote, or inhibit the translocation to the cell membrane of specific PKC isoforms to 
specific anchoring sites. This method has already been tested, with marked success, in 
animal models, where PKC α expression was decreased by the antisense oligonucleotide 
ISIS 3521 (da Rocha et al. 2002). However, in human trials, there appeared to be no dose 
limiting toxicity and clinical activity was observed in 99 cycles of treatment. However, 
the half-life of the drug was very short (18-92 minutes). Moreover, there was a dose 
dependant increase in the maximum concentration of the drug in the plasma (up to levels 
seen in primate models) and a dose dependant decrease in the drug clearance. Therefore, 
further studies, including prolonged schedules of treatment, are required to take this 
potential treatment further (Nemunaitis et al. 1999). 
 
1.9.3 PKC Isoforms and Cancer Prevention. 
With the high incidence of breast cancer in Western populations some focus of research 
has moved, almost inevitably, into its prevention. CLA is known to confer a 
chemoprotective effect on tumour initiation/development in rats (Field and Schley, 2004), 
but its mechanism of action can still only be surmised. From its effect on various different 
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PKC isoforms in the LNCaP cell line (Song et al. 2004), this unusual fatty acid shows 
several potential targets, including modulation of membrane composition and gene 
expression. It is the objective of this study to determine the effect that treatment with 
various concentrations of the two most abundant isoforms of CLA over different time 
periods have on PKC isoform expression and activation in MCF-7 and MDA-MB-231 
breast cancer cells.  
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1.10 Structural Proteins in the Cell, Claudin-3 and β Actin. 
1.10.1 Cell Junctions 
In normal, healthy human cells direct cell to cell contacts are essential for maintaining the 
normal structure, function and homeostasis of tissues. There are three basic forms of cell 
junction, each with a specific protein complex and function.  
 
1.10.1.1 Desmosomes. 
Desmosomes, also known as macular adhesions, are found on the lateral sides of the cell, 
especially in epithelial tissues. Desmosomes follow no fixed pattern in their adhesion, 
making them more resistant to shearing forces than other junctional protein complexes.  
The cadherin super family of proteins form the basis for desmosome complexes, usually 
by homophillic binding with linking proteins to form a dense “attachment plaque” 
between cells. 
 
1.10.1.2 Adherens Junctions. 
Adherens junctions are usually found at the basal membrane of the cell, either forming 
localised adhesion plaques or as zonula adhesion bands depending on the tissue type. 
Similar to desmosomes, the adherens junctions are based on a complex of cadherins, 
although they form homodimers and are anchored to actin filaments rather than keratin by 
complexes of α and β catenin. This leads to a much smaller intercellular space between 
cells than with desmosomes.  
 
1.10.1.3 Tight Junctions. 
Tight junctions are an essential mechanism if the body is to correctly control paracellular 
ion flux across tissue sheets at a cellular level, if this is not controlled then normal tissue 
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homeostasis is disturbed and cells can become prematurely apoptotic (Morin, 2005). The 
tight junction itself is thought to be composed of microdomains, spatially organised 
within the plasma membrane by the presence of sphingolipids and cholesterol (Miyoshi 
and Takai, 2005). Electron microscopy shows multiple strands forming at tight junctions, 
probably allowing structural adhesion between cells. Tight junctions prevent too much 
lateral migration by membrane bound proteins, thereby aiding the cell in its maintenance 
of polarity as well as keeping different tissue types separated. It is known that tight 
junctions are composed of three major protein families, all of which are integral to the 
structure and function of the cellular membrane; these are the claudins, the occludins and 
the junctional adhesion molecules (JAMs). Of these, the claudins are of the most interest 
to this work.  
 
1.10.2 The Claudin Super Family. 
The claudin super family comprises of 23 different isoforms (first identified in chicken 
liver by Furuse et al in 1998) which are known to be tissue specific, although most tissues 
express multiple isoforms. It is believed that the claudins form the backbone for the 
strands at the tight junction protein complex, the different isoforms combine in a tissue 
specific conformation to form homo or hetro dimers. It is thought that the combination of 
claudins within a tissue is what determines the strength of the tight junction (Morin, 
2005). 
 
Claudins are integral to the plasma membrane and comprise four membrane spanning 
domains and two extracellular loops, with the C and N terminus of the protein being 
found intracellularly. The extracellular loop which is closest to the N terminus is 
significantly larger than the C terminal loop. The larger loop also expresses a conserved 
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WWCC motif (with the structure WX(17-22)WX(2)CX(8-10)C (Turksen and Troy, 2004, 
Figure 1.7).  
 
Figure 1.7. Model Claudin showing conserved domains in extracellular loops (Morin, 
2005). 
 
It is thought that this conserved domain is what permits claudins to bind both homo- and 
heterotypically. 
 
1.10.3 Claudin-3. 
Claudin-3, along with the highly similar Claudin-4, are known to be a natural receptors 
for the Clostridium perfringens enterotoxin (CPE) (Katahira et al. 1997).  CPE is a known 
causative agent of diarrhoea, by altering the permeability of the membrane of epithelial 
cells in the intestinal tract. This altered permeability leads to fluid accumulation within 
the intestine and bowels. Sensitivity to CPE is not limited to single species, suggesting 
that it has an effect on membrane proteins with a high degree of structural similarity 
between species (Katahira et al. 1997). Katahira et al. in 1997 showed that the genes 
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encoding the functional CPE receptor (now referred to as Claudin-3) in both human and 
mouse cell lines exhibited 96.7% similarity. 
 
1.10.4 Claudin-3 and Cancer. 
Studies have shown that expression of Claudin-3 is elevated in some common tumour 
types, including bladder, ovarian, colon, prostate, uterine and breast tumours.  
Beta-actin is a 40kD protein found ubiquitously in the cytoplasm of all cells in the body. 
Because of its high expression and relative resistance to changes caused by various drug 
treatments, it is commonly used as a loading control for immunoblotting and other protein 
assays.  
 
1.10.5 Actin. 
Actin is a highly conserved protein between species, with approximately 95% of the 
protein being conserved between the primary structures of actin in Saccharomyces 
cerevisiae and Homo sapiens. This conservation is mostly due to the use of actin 
filaments in binding to a large number of disparate proteins within the cell. Mammals 
express 6 different isoforms of actin, designated α, β, and γ, which are involved in cell 
integrity, structure and motility. It is known that ß-actin mutations are responsible for a 
number of developmental midline malformations, including harelips and cleft palates, as 
well as problems like hearing loss and the generalised movement disorder dystonia 
(Procaccio et al. 2006).  
 
1.10.6 ß-actin as a Loading Control for Western Blot Analysis.  
Currently, ß-actin is the loading control of choice for many different cell treatments and 
proteins for researchers carrying out Western blot analysis and enzyme linked 
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immunosorbent assays (ELISA). As a loading control, ß-actin is almost ideal as it is 
mostly uninfluenced by a wide variety of cell treatments, and is expressed abundantly and 
with very little change in many of the different cell lines currently available. It is worth 
noting, however, that in 2006 Dittmer and Dittmer suggested that at higher protein loads, 
and over longer incubation times it is much less sensitive to changes in protein loading, 
due to its high cellular abundance. ß-actin is also only found in the soluble protein 
fraction; not in the insoluble fraction meaning that it is also unsuitable for detecting 
protein loading for membrane bound proteins. It is for this reason that an important 
developmental part of this study will be to determine whether or not Claudin-3 can be 
considered as an effective loading control for membrane- bound proteins extracted from 
MCF-7 and MDA-MB-231 cells previously treated with different isomers of CLA.  
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1.11 Experimental Aims of the Current Research. 
Since the discovery of the PKC isoforms, their known regulation by tumour promoters 
like phorbol esters and their impact on tumorogenisis in the 1980’s, much work has been 
done to elucidate their mechanism of action and to discover compounds which act 
specifically on individual isoforms to enhance or decrease their individual properties.  
 
Studies in prostate cancer cells suggest that CLA isoforms may be an effective means of 
causing tumour shrinkage and apoptosis (Song et al. 2004), due, at least in part, to their 
apparent ability to enhance the activation of the pro-apoptotic PKC isoforms and to 
decrease the activation of the anti-apoptotic ones. It is notable that similar experiments 
have not yet been performed using breast cancer cells. It is, therefore, the focus of this 
research to study whether CLA’s have similar effects in breast cancer cells to those 
observed in prostate cancer cells and, if so, which of the selected isoforms of PKC show 
activation or inactivation in the MCF-7 and MDA-MB-231 lines of cancer cells (by 
translocation of PKC to the cellular membrane, or sequestering within the cytosol) after 
treatment with individual isoforms or a mix of the two main isoforms.  
 
The mechanism of PKC activation by CLA isoforms in breast cancer cell lines is also of 
interest, as future work to develop CLAs as either a defence against cancer (preventative), 
or as an adjunct to conventional cancer therapy (treatment) must hinge on how the 
isoforms affect the cell as a whole. 
 
These studies are part of a larger study that is investigating the role of various nutrients 
and nutraceuticals as possible chemopreventive and adjunct chemotherapeutic agents. 
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These aims will be realised by a variety of techniques, including Western Blotting, and 
protein analysis, RT-PCR, and cell culture. 
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Chapter 2. 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 55 
2. Materials and Methods 
2.1 Materials 
 Foetal Bovine Serum (FBS) was purchased from Perbio, UK, 1mM Sodium Pyruvate and 
2% Penicillin/Streptomycin from Invitrogen, UK. RPMI 1640 medium containing 
GlutaMAX™ 1 and 25mM HEPES buffer, from Fisher, UK. 
 
Pure Conjugated Linoleic Acid, Linoleic acid isomers  and 98% pure Bovine Serum 
Albumin (BSA) was purchased from Sigma. Calbiochem ProteoExtract Native Protein 
Extraction kit was from Calbiochem. 10k centrifugal filters were from Pall. Alkaline 
copper tartrate solution (Reagent A), dilute Folin reagent (Reagent B) were from Bio-Rad.  
Pre-stained Protein Marker, Broad Range (6-175 kDa) was bought from New England 
Biosciences, USA. PVDF membrane was bought from GE Healthcare, UK and 3mm 
chromatography paper from Fisher, UK. X-Ray Photographic Film, Developing solution 
and Fixing Solution were all purchased from Kodak, UK. SuperSignal West Pico 
Chemiluminescent kit; Luminol Enhancer, and Stable Peroxide, and Restore Plus Western 
Blot Stripping Buffer, both bought from Pierce, USA. Gel Electrophoresis, and Western 
Blot equipment were all supplied by Bio-Rad. Trizol (phenol based solution), and DEPC 
treated water were purchased from Sigma, chloroform, ethanol, and Isopropyl alcohol, 
were all supplied by Fisher. iCycle, Thermocycler unit supplied by Bio-Rad, 
Spectrophotometer supplied by Heλios.  
 
The following buffers were made up; SDS Loading Buffer (190mM Tris, pH 6.8, 30% 
Glycerol, 6% SDS, 150mM DTT, 0.15M bromophenol blue. Running Buffer (250mM 
glycine, 25mM Tris, 0.1% SDS). Wet Transfer Buffer (10% running buffer, 20% 
Methanol, 70% water). Tris Buffered Saline with Tween-20 (TBS-T) (20mM Tris, 0.13M 
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Sodium Chloride, 0.1% Tween-20, pH 7.6). Blocking Buffer (50mM TBS-T, 5% 
Skimmed, dried milk, (Marvel®)). Ponceau Red Stain (0.1% Ponceau R, 0.5% Acetic 
acid). Acridine Orange/Ethidium Bromide (100µg/ml Acridine Orange, and 100µg/ml 
Ethidium Bromide in PBS). Trypan Blue (0.4 % Trypan blue in PBS). 
 
All plasticware from Fisher, UK, unless otherwise stated. All chemicals were Sigma, UK, 
unless otherwise stated. 
 
2.2 Cell Culture 
2.2.1 Cell Lines 
Breast cancer cell lines MCF-7 (oestrogen receptor positive) and MDA-MB-231 
(oestrogen receptor negative) were a gift from Professor Steve Heys (Department of 
Surgery, University of Aberdeen, UK), and routinely cultured in RPMI 1640 medium, 
supplemented with 10% FBS, 100µg/ml Sodium Pyruvate and 100µg/ml Penicillin/ 
Streptomycin. Cells were incubated at 37˚C in a 5% CO2 atmosphere and passaged every 
3 to 4 days at approximately 80% confluence. 
 
2.2.2 Recovering Cells from Liquid Nitrogen 
The cell vial was removed from the liquid nitrogen storage and incubated for 10 minutes 
at 37˚C; cell suspension (1ml) was decanted into a culture flask containing 19ml of 
supplemented culture medium. The cells were allowed to settle overnight at 37˚C after 
which the medium was removed and the cells gently washed with PBS, followed by the 
addition of fresh supplemented medium (20ml). 
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2.2.3 Procedure for Cell Subculture 
Cells were grown in standard 75cm2 tissue culture flasks. Once confluence had been 
reached the medium was discarded and the cells washed twice with sterile PBS. Trypsin 
(2ml) was added and the cells were incubated at 37˚C for 1-2 minutes. Once the cells 
were detached, the trypsin was inactivated by the addition of 18ml of the supplemented 
medium and the cells aspirated through a 19G hypodermic needle to give a uniform cell 
suspension. Fresh supplemented medium (20ml) was added to the flask and the suspended 
cells were divided equally between two flasks which were incubated as previously stated 
until confluence. 
 
2.2.4 Freezing Cells for Storage 
Cells at confluence were washed twice with PBS and detached from the flask as described 
above. After trypsinisation 10 ml of the unsupplemented RPMI 1640 medium was added, 
the cells transferred into a 50ml Falcon tube and centrifuged for 8mins at 380g. The 
supernatant was discarded, 100µl of unsupplemented medium, 1.8ml FBS added along 
with 100µl of DMSO were added to the cells, which were then resuspended and the 
mixture aliquoted into two Cryovials (1ml/cryovial). The cryovials were placed in an 
isopropanol bath (“Mr Frosty”) to insure a steady rate of freezing at 1˚C per minute when 
placed at -80˚C for 24 hours. The vials were then transferred from the freezer into Liquid 
nitrogen for long term storage. 
 
2.3 Staining Cells for Counting 
2.3.1 Supplementation with Conjugated Linoleic Acid 
100mM stock solutions of pure Conjugated Linoleic Acid isomers (c9:t11, t10:c12 and a 
50:50 mix of the two isomers), and Linoleic acid dissolved in 100% ethanol (Fisher) were 
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diluted to give test concentrations of 25 and 50µM. Stock solutions were stored at -20˚C 
under gaseous nitrogen. 
 
2.3.2 Acridine Orange/ Ethidium Bromide Uptake 
Cells were plated onto 6 well plates at an approximate density of 100,000 cells per well. 
0.5ml of 100% confluent cell suspension from a standard T80 tissue culture flask was 
diluted in 2.5ml of medium. Plates were incubated at 37˚C for 24 hours to ensure 
adequate cell adherence to the plate. Cells were then treated with either 25 or 50µM of 
Conjugated Linoleic acids, as detailed in section 2.3.1. Plates were incubated at 37˚C for a 
further 24 hours, and the medium removed. Cells were washed twice with PBS and 40µl 
Acridine Orange/Ethidium Bromide dye solution, diluted in 1ml PBS was added to each 
of the wells. Plates were incubated at room temperature for 2 minutes and cells viewed 
under a Leica DC 200 Fluorescence Microscope. 
 
2.3.3 Trypan Blue Dye Exclusion 
Cells in T80 flasks were brought to confluence and supplemented with Conjugated 
Linoleic Acids for 24 hours as stated in section 2.3.1. Cells were detached from the flask 
using Trypsin as detailed in section 2.1.4. Trypsinised cells were suspended in the 
medium, and 0.5ml of cell suspension was mixed with 0.5ml of Trypan Blue. 20µl of the 
suspension was added to the counting chamber of a haemocytometer and viewed under a 
10X objective microscope. Both total cells and non viable cells were counted. 
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2.4 Protein Extraction 
2.4.1 Supplementation with Conjugated Linoleic Acid 
Supplementation with Conjugated Linoleic Acid was carried out exactly as stated in 
section 2.3.2. 
 
2.4.2 Protein Extraction 
Cells at confluence were incubated with fatty acids at the required concentrations (25 or 
50µM) for 24hr. After incubation cells were washed once with cold PBS, scraped from 
the flask and transferred into 15ml centrifuge tubes. Cells were then centrifuged at 1000g 
for 5 minutes at 4˚C. The proteins were extracted using the Calbiochem ProteoExtract 
Native Protein Extraction kit following the manufacturer’s protocol: the PBS was 
discarded and cells re-suspended in ice-cold Wash Buffer (2ml), the cells were then 
centrifuged at 1000g for 5 minutes at 4˚C. This process was repeated once more with 
fresh Wash Buffer. The excess buffer was carefully aspirated from the cell pellet and 
Protease Inhibitor Cocktail (10µl) and ice-cold Extraction Buffer I (2ml) were added to 
the cells. The cells were then incubated at 4˚C for 10 mins under constant agitation to 
prevent the formation of clumps. The insoluble material was centrifuged at 16,000g and 
4˚C for 15 mins: the supernatant contained the soluble cytosolic proteins. The supernatant 
was collected and stored at -80˚C until further analysis. Protease Inhibitor Cocktail (5ml) 
and ice-cold Extraction Buffer II (1ml) was added to resuspend the pellet (i.e. the 
insoluble material). The cells were then incubated at 4˚C for 30 mins, as before and 
centrifuged at 16,000g and 4˚C for 15 mins. The supernatant containing all the insoluble 
membrane bound proteins was collected for storage at -80˚C until used for protein 
concentration determination before Western Blot analysis. 
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2.4.3 Concentration of cytosolic protein fraction 
The cytosolic protein fraction obtained from the MDA-MB-231 cells was centrifuged 
through a 10k centrifugal filter to remove excess buffer at 3000g and 4˚C for 140 mins. 
 
2.4.4 Protein assay 
Protein sample concentration was determined using an adapted method from the standard 
one set out by Lowry et al. in 1951. Protein concentrations of the samples obtained above 
were determined against a standard curve of the following protein concentrations 0, 0.5, 1, 
1.25, and 1.5mg/ml read at 620nm. 5µl duplicates of each protein fraction were used, and 
made up to 25µl with distilled water. 25µl of Reagent A and 200µl of Reagent B were 
added to each sample and incubated for 15mins. Absorbance was read using a Dynex 
Technologies, MRX II microplate reader. 
 
2.5 Gel Electrophoresis and Western Blotting 
 
Table 2.1. Make up of resolving polyacrylamide gels (4 gels) 
Gel concentration 7% 9% 12% 15% 
Acyle:Bis (29:1) 3.3ml 4.4ml 5.7ml 7.1ml 
Tris 1.5M pH 8.8 4.6ml 4.6ml 4.6ml 4.6ml 
Distilled H2O  10.9ml 9.7ml 8.4ml 7.0ml 
APS 10% 150µl 150µl 150µl 150µl 
TEMED 15µl 15µl 15µl 15µl 
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2.5.1 Gel Electrophoresis of Protein Samples 
4% polyacrylamide stacking gels and 12% separating gels were used to perform Sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) based on the method 
described in 1970 by Laemmli et al.. The following protocol was used: 
The resolving gel was cast in a glass mould (see table 2.1 for gel make up), and allowed to 
set under a layer of water saturated buthanol for 20mins, the buthanol was removed, and a 
layer of stacking gel was added along with a comb used to create the wells. Initially 40µg 
of protein sample (determined by Lowry microassay) was denatured by boiling in 3µl of 
SDS loading buffer for 7mins. The samples were loaded onto the gel with a protein 
marker in the first, and final lanes and the gels run in the running buffer at 200 volts.  
Samples were run for 90mins. 
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Table 2.2 Antibody origin, specificity, and dilution. 
Antibody Raised in Primary/Secondary Working Dilution 
PKC α (Abcam) Mouse Primary 1:1000 
PKC δ (Abcam) Rabbit Primary 1:1000 
PKC ι (Santa Cruz) Rabbit Primary 1:1000 (cytosolic 
sample)  
1:2000 (membrane 
sample) 
Beta-Actin (Sigma) Mouse Primary 1:30000 
Claudin-3 (Abcam) Goat Primary 1:500 
Goat anti Mouse 
IgG (Santa Cruz) 
Goat Secondary 1:2000 
Goat anti Rabbit 
IgG (Santa Cruz) 
Goat Secondary 1:2000 (cytosolic 
sample)  
1:5000 (PKC ι 
membrane sample) 
Rabbit anti Goat 
IgG (Santa Cruz) 
Rabbit Secondary 1:10000 
 
2.5.2 Western Blotting 
After the proteins had fully separated within the gel matrix they were transferred from the 
polyacrylamide gel to the PVDF membrane using a wet electro-blotting protocol. The 
stacking gel was removed and discarded. The separating gel soaked in wet transfer buffer 
solution. The membrane was soaked in methanol for approximately 10secs and then 
washed in deionised water. The cassette was stacked from the positive side upwards (See 
Fig 2.1); a piece of sponge, well soaked in buffer was placed on the positive surface. 3 
pieces of 3mm chromatography paper (5x9cm) were stacked on the sponge after being 
briefly soaked in the buffer and air bubbles removed by rolling a Pasteur pipette across 
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the surface. The membrane was placed on the paper and the gel on the membrane with a 
further three soaked pieces of chromatography paper on top. Any air bubbles were 
carefully removed and a further sponge soaked in buffer placed on top of the pile, the 
apparatus was then assembled and the proteins transferred for 45mins at 300 volts.  
 
 
Figure 2.1 Protein transfer stack for wet electro blotting protocol. 
 
After the transfer was completed, the membrane was incubated in blocking buffer (as 
detailed previously) for up to two hours. The membrane was incubated overnight at 4˚C, 
on a roller shaker, with 5ml of antibody solution (where the antibody was diluted in 
blocking buffer; see table 2.2 for antibody and dilutions). The membrane was washed 3 
times for 10mins each in TBS-T, and incubated for one hour at room temperature with the 
secondary antibody diluted as before (see table 2.2 for dilutions), rotating constantly. The 
membrane was then washed 3 times for 10mins each in TBS-T. 
 
The bands were visualised using X-ray film. The membrane was covered with 2ml of 
stable peroxide solution and 2ml of luminol / enhancer solution and allowed to incubate at 
room temperature for 5 mins. The membrane pieces were blotted to remove excess 
enhancer solution, and wrapped in a single layer of colourless Saran food wrap. The light 
sensitive photographic film was exposed to the treated membrane in for a period of 
between 30secs and 10mins, the film was then treated with developing solution for 2mins, 
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briefly rinsed in water, immersed in fixer solution (1min) and washed once more in water. 
The film was allowed to dry overnight.  
 
Membranes on which the cytosolic protein samples were run were stripped using 10ml of 
Restore Plus Western Blot Stripping Buffer at 37˚C for one hour, rotating constantly. 
Membranes were blocked in blocking buffer for a further 1 hour, and re-probed with 
either Beta-Actin (for proteins in the cytosolic fraction) or Claudin-3 (for proteins in the 
membrane bound fraction) antibodies (See table 2.2) 
2.5.3 Staining membranes with Ponceau Red. 
After transfer or detection membranes were stained for 5 minutes in Ponceau Red 
solution. Then, the membranes were de-stained for 30 seconds in 50ml deionised water, 
then blotted to remove excess moisture and allowed to air dry at room temperature. 
 
2.6 RT-PCR 
2.6.1 Total RNA extraction 
Cells at confluence were lysed with 1ml of Trizol, and incubated for 2 minutes at room 
temperature. The cell lysate was passed through a pipette tip several times to ensure 
proper mixing, then transferred to an RNAse free microcentrifuge tube. The cell lysate 
was then incubated for a further 5 minutes at room temperature. Chloroform (200µl) was 
added to the cell lysate, and shaken for 15 seconds; the mixture was again incubated at 
room temperature for 2 minutes. Tubes were centrifuged at 15300g and 4˚C for 15 
minutes, and the aqueous phase of the supernatant was transferred to a new tube. The 
aqueous phase had 500µl of isopropyl alcohol added and was mixed gently, then 
incubated at room temperature again for 10 minutes. The mixture was then centrifuged at   
15300g at 4˚C for 10 minutes to precipitate the RNA. The supernatant was removed, and 
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the pellet washed with ethanol (75%) and DEPC treated water. The pellet was mixed and 
centrifuged at 15300g and 4˚C for 5 minutes. The pellet was allowed to air dry and then 
covered with DEPC treated water. The pellet was frozen at -20˚C over night, then 
dissolved by incubating at 65˚C for 10 minutes, and mixing gently. 
 
2.6.2. RNA assay  
RNA was assayed for concentration and purity using a Heλios γ Spectrophotometer 
(Thermo Spectronic). The extracted RNA was diluted to a ratio of 1:200 in DEPC treated 
water, and placed in a glass curvette. The OD260, and OD280 readings were measured, and 
the RNA concentration calculated using the formula: 
Concentration (µg/µl)   =   OD260 x 40 x Dilution factor 
                                                             1000 
 
Sample purity was obtained by the formula: 
 
Purity  =  OD260 
                OD280 
With a purity of 2 being very pure, and a purity of less than 1.3 being of poor quality, and 
causing the samples to be discarded. 
 
2.6.3 Poly-dT two step PCR 
For the RT reaction step, 1µl total RNA, with 4µl 5x first strand buffer, 2µl DTT, 2µl 
dNTP’s, 1µl RNAse out, 2µl BSA, 1.5µl poly-dT primers, 0.4µl Superscript II RNAse H 
RT and DEPC treated water was placed in 0.5ml eppindorf tubes, and placed in a BioRad 
Thermal Cycler at 37˚C for 60 minutes, then at 95˚C for a further 10 minutes. A PCR 
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master mix was made up, comprising; 8.8µl DEPC treated water, 1.6 µl of pre mixed 
buffer without magnesium chloride (MgCl2), 1.4µl of MgCl2, 2µl each of the forward and 
reverse PCR primers (see table 2.3), and 0.2µl of Taq polymerase. After removel from the 
Thermal Cycler the RT mix was allowed to cool on ice for 1 minute, then 4µl per tube 
added to 16µl of the PCR master mix, along with an equal volume of distilled water for 
the blank samples. Samples were mixed and transferred to the Thermal Cycler, for 35 
cycles (25 cycles for ß-actin, see table 2.4) 
 
Table 2.3 Make up of PCR primer pairs 
Protein Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
ß-Actin CAT GTA CGT TGC TAT CCA 
GGC 
CTC CTT AAT GTC ACG CAC 
GAT 
PKC α CTG CTT CCA GAC AGT GGA 
TCG 
GCC GCA TAG AAT ACT GCT 
TGT 
PKC δ GAG GCC AAG TTC CCA ACG 
AT 
TGC ATT TGT AGC CTT GCT 
TGT 
PKC ι CAC CAG GTC CGG GTG AAA 
G 
TGA AGA GCT GTT CGT TGT 
CAA A 
 
Table 2.4 Cycles of Hot-Start PCR 
Cycle (repeats) Temperature (˚C) Time (Mins) 
1 (1) 94 4:00 
2 (35) 94 1:00 
 59 2:00 
 72 2:00 
3 (1) 72 8:00 
4 (∞) 4 ∞ 
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2.6.4 DNA Electrophoresis on Agarose Gel 
50ml, 1% Agarose gels were made up using pre-mixed 1xTBE buffer, and 2.5µl 10mg/ml 
Ethidium bromide solution. Gels were cast in a plastic mould with two 20 well combs. 
Samples and 100bp DNA ladder were loaded with 3µl of pre-mixed loading buffer and 
run in pre-mixed 1xTBE buffer for 30 minutes at 80 volts. Gels were photographed, and 
analysed using a Bio-Rad ChemiDoc™ EQ imaging device. 
 
2.7 Analysis of Results. 
2.7.1 Protein Quantification 
After detection the protein was quantified using a Bio-Rad ChemiDoc™ EQ imaging 
device, and the associated Quantity One 1D Analysis software v.4.5.0 (Microsoft 
Windows compatible version). The software measures the signal intensity of each band in 
units of optical density (OD). Protein quantity (%) was expressed relative to an ethanol 
control (100%) of equivalent volume. 
 
2.7.2 RNA Quantification 
After detection the RNA was quantified using a Bio-Rad ChemiDoc™ EQ imaging 
device, and the associated Quantity One 1D Analysis software v.4.5.0 (Microsoft 
Windows compatible version). The software measures the signal intensity of each band in 
units of optical density (OD). RNA quantity (%) was expressed relative to an ethanol 
control (100%) of equivalent volume. 
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2.7.3 Statistics 
All data is expressed as a mean value of n=6 samples from 3 independent experiments, all 
data is shown with the standard errors of 6 observations. The results of the protein, and 
RNA quantity were all treated with a standard Mann-Whitney paired t-Test to determine 
statistical significance, considered at a P value of <0.05, of each treatment against the 
mean control value. 
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Chapter 3. 
Optimisation and Development of the Various Techniques Utilised in the 
Current Research 
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3. Optimisation and Development of the Various Techniques Utilised in the Current 
Research 
 
Every method requires optimisation to ensure it works to its optimal efficiency. Even a 
method which works perfectly with one piece of equipment may not work as well with 
another. 
 
3.1 Protein Extraction 
3.1.1 Initial methods used. 
On starting this research there were no readily available and reliable kits for extracting 
both membrane bound, and cytosolic protein separately. It was possible to purchase kits to 
extract the total protein (cytosolic and membrane bound together), or to extract either 
separately, however this separate extraction usually resulted in the contamination of the 
other protein fraction in some way that rendered it unsuitable for use in a Western Blot. 
 
Initially the method which was used involved ultracentrifugation, which provided some 
problems, one of the biggest was the initial lack of a suitable ultracentrifuge rotor capable 
of accepting 1.5ml ultracentrifuge tubes, required due to the small sample volumes being 
collected. The second problem was that this method was not particularly efficient; either 
at separating the cytosolic and membrane bound protein fractions, or at extracting the 
majority of membrane bound proteins from the membrane. It was only after considerable, 
detailed investigation of the localisation of ß-actin within the cell that it was accepted that 
the presence of ß-actin within the membrane bound protein fraction (Fig 3.1) was 
indicative of poor separation.  
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Fig 3.1 ß-actin presence in the Membrane Bound protein fraction. ß-actin as observed in 
the cytosolic and the membrane bound protein fractions after extraction by 
ultracentrifugation. 
 
 
In 2006, new membrane bound protein extraction kit had become available (Calbiochem 
ProteoExtract Native Protein Extraction kit), which produced a much better separation 
(Fig 3.2).  
 
Fig 3.2 Separation of ß-actin and Claudin-3. ß-actin and Claudin-3 from samples 
extracted using the Calbiochem ProteoExtract Native Protein Extraction kit (initial 
results, not fully optimised, but indicative of seperation). 
 
3.1.2 Optimising the Calbiochem ProteoExtract Native Protein Extraction Kit. 
The extraction kit produced a new challenge; that the cytosolic protein fraction was very 
dilute, sometimes so much so that the volume of extract required to load 40µg of protein 
was greater than the actual capacity of the well. There are several methods of 
concentrating down protein; it was decided to investigate the use of commercially 
available centrifugal filters as they appeared to offer the best chance of retaining all the 
proteins of interest.  
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To concentrate the protein to an acceptable level several centrifugal filters, from several 
different companies were investigated. It was determined that the optimal filter would 
have a molecular weight exclusion point of 10kD or less, this would ensure retention of 
all the proteins of interest, while removing the excess buffer. The filter was also required 
to be capable of filtering volumes of samples between 1 and 5 ml, filters only capable of 
handling smaller amounts would not be any use with a sample volume of 2ml, and filters 
with a greater capacity run the risk of either not filtering enough buffer, or spinning to 
dryness, leaving the proteins stuck to the filter membrane. Only one filter was considered 
to meet the criteria, the Pall, Gelman Microsep 10K Omega. The filter was first rinsed by 
spinning at 3000g for 15 minutes with distilled water (as per manufacturers 
recommendations). The cytosolic fraction collected using the Calbiochem ProteoExtract 
Native Protein Extraction kit was then spun, again at 3000g. The manufacturer 
recommended that the first spin should be of no more than 80 minutes at the lowest 
effective speed (3000g). If an acceptable solute concentration was not achieved then it 
was recommended that either the speed of centrifugation (up to 7500g), or the spin time 
be increased. The first trial proved very successful, with 140 minutes of spin at 3000g and 
4˚C leading to an eightfold increase in protein concentration (Fig 3.3). 
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Fig 3.3: Centrifugal Concentration of cytosolic protein. Concentration of proteins by 
Pall, Gelman Microsep 10K Omega filters. Protein concentrations determined by Lowry 
Assay after 0, 80, and 140 minutes at 3000g. 
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3.2 Western Blotting 
Western Blotting and gel electrophoresis appear to be particularly sensitive to a myriad of 
small changes, including ambient temperature, and humidity. The two methods for 
Western Blotting, currently in use are known as “wet”, and “semi dry”. Both have a 
theoretically equal chance of success, and opinion appears to be divided as to which 
works most consistently. During the course of this work both the wet, and the semi dry 
method have been used, and refined in an attempt to obtain reliable results.  
 
3.2.1 Semi Dry Western Blotting 
The semi dry method has the advantage of requiring much less buffer, which helps to 
keep costs down. The system required a constant pressure to ensure that the current was 
being passed equally through the whole surface of the gel. If the pressure was unequal 
then the proteins nearest the top of the machine (where the electrodes plugged into the 
power pack) were transferred with greater fidelity due to a greater pressure at one end, 
due to this a large amount of protein was found to be left within the gel (Fig 3.4) after 
transfer.  
 
 75 
 
Fig 3.4 Comassie Blue staining of a Gel. Showing poor protein transfer. 
 
Results gained using this equipment were inconsistent, and frequently of poor quality (Fig 
3.5). 
 
Fig 3.5 Poor transfer of protein. An example of results gained using the Biometra Semi-
Dry Electroblotter. The protein being observed in this example is PKC α. 
 
3.2.2 Wet Western Blotting 
Wet Western blotting has been carried out throughout using a Bio-Rad Mini Proteon-3 
transfer kit. The wet method has, so far, during the course of this research proved to be the 
most reliable, with approximately 80% of the experiments performed working first time. 
For proteins of up to 100kD it was found that this system produced clear, consistent 
results, however for larger proteins (>150kD) transfer is still of poor quality. Fortunately 
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in this work the various PKC isoforms all have a molecular weight of less than 100kD, as 
do the Claudin-3 and ß-actin used as loading controls. 
 
3.2.3 Western Blot Buffer 
Wet and Semi-Dry blotting both require the same buffer for correct transfer, this buffer 
composition is very important as it provides the electrolytes required to carry an electric 
charge, and the SDS which imparts a negative charge to the proteins, allowing them to 
migrate towards the positive electrode. Originally buffer without SDS was used with the 
Semi-Dry blotting, but this was found not to work at all. The pH of the buffer is also 
important, but it was found that adding sodium hydroxide to increase the pH was affecting 
the migration of the protein. The ideal pH for the buffer should be 8.8, however the actual 
pH is more usually around 8.3 – 8.4, which is still well within the acceptable range. Too 
high (or too low) a pH often causes overheating of the buffer, and consequently 
overheating of the gel, as well as causing poor mobilisation of the proteins. 
  
3.2.4 Western Blot Antibodies 
Each specific antibody used during these experiments required careful optimisation. 
Because not all the antibodies were ordered from the same source there was a mixture of 
mono- and poly- clonal types, as well as different species, this necessitated using several 
different blocking agents and strengths. Monoclonal antibodies often exhibit a higher 
background when blocked with skimmed dried milk, compared to BSA, while polyclonal 
antibodies appear to give better results with skimmed dried milk. The extreme specificity 
of monoclonal antibodies also leads to masking at higher concentrations, while polyclonal 
antibodies exhibit excessive banding if the concentration is too low.  
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From the optimisation experiments performed it was determined that a buffer made up of 
3% BSA in TBS-T worked best for the monoclonal antibodies used, while 5% skimmed 
dried milk was better for the polyclonal antibodies. The only real exception to this was the 
Claudin-3 antibody, which was from a monoclonal culture raised in goat rather than in 
rabbit or mouse. Goat antibodies show a tendency to bind very strongly to BSA, leading 
to a very high background, however, this was reduced considerably by blocking in 5% 
non fat milk. Initially high background dogged all the antibodies used, with the exception 
of  ß-actin which had been previously optimised, changes to the concentration and type of 
blocking buffer either resulted in masking, (no, or very little signal seen), or high 
background. All membranes were being washed for 3x10 minutes in a 0.1% solution of 
TBS-T, and increasing the washing time was only marginally effective, however, it was 
eventually determined that washing with a 0.5% solution  of TBS-T almost completely 
eliminated the background, with the higher concentration of detergent acting to remove 
loosely bound antibody. 
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3.3 Development of an Elisa Assay for PKC α 
The Enzyme-Linked Immunosorbent Assay (ELISA) is a similar technique to the Western 
Blot, involving, as it does, an unknown amount of antigen being affixed to a surface, 
usually a 96 well plate, the plate is then incubated with a  specific antibody (in this case 
PKC α). This antibody is tagged with an enzyme, usually either Horseradish Peroxidase 
(HRP), or alkaline phosphatase (AP). After incubation the specific substrate is added, and 
a fluorescent or colorimetric reading is taken, this reading is then compared to standards 
of a known antigen amount. This method is known as an “indirect” ELISA (Fig 3.6), but 
there are other variations, including the “Competitive” ELISA (Fig 3.7), and the 
“Sandwich” ELISA (Fig 3.8). As there were no commercially available kits for detection 
of the separate PKC isoforms development of one was considered a viable option. 
 
 
Figure 3.6 Indirect ELISA Method 
 
Figure 3.7 Competitive ELISA Method 
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Figure 3.8 Sandwich ELISA Method 
 
Competitive ELISAs involve the incubation of unlabeled antibody with its specific 
antigen. The antibody/antigen complexes are then added to an antigen coated well. After 
washing to remove any unbound antibody a specific secondary antibody is added which 
binds to the primary, this secondary antibody is tagged with either HRP or AP and the 
signal intensity is again read. The Sandwich ELISA was considered to be the most 
effective type of ELISA assay for the purpose of this experiment. A known quantity of 
monoclonal primary antibody was bound to the wells, and all non specific binding sites 
were blocked using a BSA based blocking buffer. The plate was incubated with the 
protein sample, and a second, tagged primary antibody. As in other ELISA assays the 
signal intensity was read, and compared to the standard curve. 
 
The Sandwich ELISA was the assay type of choice as it picks up a small concentration of 
antigen with greater fidelity than either the Indirect or the Competitive ELISAs. This was 
especially important as the PKC isoforms are not present in any great quantity within the 
cell, and as such the indirect and competitive ELISA assays would be less effective. 
 
There were several complications involved with developing a Sandwich ELISA specific 
to PKC α. Development of an assay for the specific PKC isoforms was considered to be 
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desirable from a commercial viewpoint. Unfortunately due to budgetary and time 
constraints the project had to be abandoned.   
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3.4 Development of an “In-Gel” detection method. 
“In-Gel Technology provides a more accurate representation of relative protein levels 
than traditional Western Blotting.” Pierce In-Gel Chemiluminescent 
Detection; www.piercenet.com. 
 
This is the claim about the only in-gel protein detection system currently available, 
manufactured by Thermo Fisher Scientific Inc (Rockford Il). The theory suggests that by 
detecting proteins within the Polyacrylamide gel, rather than transferring them to a 
membrane a more accurate picture of protein expression can be gained as there should be 
minimal protein loss through the electrophoresis stage. There is also the possibility that 
this method can detect proteins in their native form. 
 
The method is comparatively simple, the protein sample is run on a Polyacrylamide gel 
(Pre-cast or homemade), along with any blanks and standards required. The gel is then 
pre-treated with either 50% Isopropanol or Methanol to allow antibody penetration. The 
gel is incubated with primary antibody, then washed with PBS-T, and then incubated with 
the secondary antibody and washed again. The secondary antibody is tagged with 
Horseradish Peroxidase, so chemiluminescence with stable peroxide solution and 
enhancer is performed as in Western blotting. The gel can then be photographed using 
either light sensitive film, or a specialized CCD camera (for example a Bio-Rad Gel Doc 
system). The gel may be stripped and re-probed with another primary antibody as 
required. 
 
The advantages of this system are obvious, cost wise it is more advantageous than the 
traditional Western Blotting after optimization, because, in theory less can go wrong, and 
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fewer experiments have to be performed, the quality of the results is also theoretically 
much better. In terms of time saved it is also very good. Where a traditional Western Blot 
takes two days to perform, as the primary antibody needs to be incubated over night, the 
In-Gel system takes less than a day, time being saved by not performing the Transfer step 
or the blocking step, and a much shorter time required to incubate the gel with the 
antibody. 
 
The disadvantages to this system are perhaps less obvious. First, and most importantly, 
the amount of protein required for detection is in the region of one nanogram, a relatively 
easy amount to load for a highly expressed and abundant protein like ß-actin, a much 
more difficult prospect when dealing with a less abundant protein like any of the PKC 
isoforms, especially PKC ι. For this reason it was not possible to utilise, or fully optimise 
this method. 
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Chapter 4. 
Viability of Breast Cancer Cells After 24h Treatment with CLA and LA.  
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4. Cancer Cell Viability After Treatment with 25 or 50µM of CLA for 24 Hours. 
4.1 Introduction 
Measuring the viability of cells in culture after the addition of a pro-, or anti-apoptotic 
agent is an important method for determining how the agent in question may affect cancer 
cells in vivo. There are several methods for determining cell viability, most relying on 
dyes, to measure the proportion of cells undergoing apoptosis and necrosis.  
 
For the purpose of this experiment Trypan Blue dye was used to stain the cells prior to 
manual counting using a haemocytometer and light microscope. 
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4.2 Results  
Viability of MCF-7 and MDA-MB-231 Cells After Treatment 
4.2.1 MCF-7 Cells treated with 25µM of CLA for 24 hours. 
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Fig 4.1: MCF-7 Cell viability after treatment with 25µM CLA. Percentage of viable 
cells after 24 hours treatment with 25µM CLA. Average of three experiments, cells 
incubated with Trypan Blue. 
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 (*) 
 
 
MCF-7 cells treated with Linoleic acid (25µM) showed no significant cell death 
compared to the control. The cells treated with the 50:50 mix of isomers were, on average, 
23.6% less viable than the control. Cells treated with the 9:11 isomer alone were, on 
average 24.5% less viable compared to the control, and cells treated with the 10:12 isomer 
alone showed the smallest decrease in viability, with a drop of 17.1% (Fig 4.1). A 
standard one way ANOVA test applied to these results showed that there were no 
significant differences between the control and Linoleic acid values or between the Mix 
and 9:11 values. There were significant differences however, between the Mix and 9:11 
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values when compared to the 10:12 value, and between the Mix, 9:11 and 10:12 values 
compared to the control (Table 4.1, Appendix B). 
 
4.2.2 MCF-7 Cells treated with 50µM of CLA for 24 hours. 
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Fig 4.2: MCF-7 Cell viability after treatment with 50µM CLA. Percentage of viable 
cells after 24 hours treatment with 50µM CLA. Average of three experiments, cells 
incubated with Trypan Blue. 
Key: Control – 100% ethanol (equivalent volume); LA – 50µM Linoleic Acid; Mix – 
50µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 50µM c9:t11 isomer alone; 
10:12 - 50µM t10:c12 isomer alone. P<0.05 
 
MCF-7 cells treated with 50µM of Linoleic acid showed no significant cell death 
compared to the control. The cells which were treated with the mix of isomers were on 
average 32.4% less viable than the control, cells treated with the 9:11 isomer alone were 
on average 39.4% less viable compared to the control, and the cells treated with the 10:12 
isomer alone again showed the smallest decrease in viability, with a drop of 32.1% (Fig 
4.2). An ANOVA test showed no significance between the values for the Mix, 9:11 and 
10:12 isomers, or between the control and Linoleic acid values. There was however, a 
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significant difference between the Mix, 9:11 and 10:12 values and the control (P<0.05) 
(Table 4.2, Appendix B). 
 
4.2.3 MDA-MB-231 Cells treated with 25µM of CLA for 24 hours. 
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Fig 4.3: MDA-MB-231 Cell viability after treatment with 25µM CLA. Percentage of 
viable cells after 24 hours treatment with 25µM CLA. Average of three experiments, cells 
incubated with Trypan Blue. 
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 
 
MDA-MB-231 cells treated with 25µM of Linoleic acid showed no significant cell death 
compared to the control. The cells which were treated with the mix of isomers were on 
average 44.4% less viable than the control, cells treated with the 9:11 isomer alone were 
on average 39.6% less viable compared to the control, and the cells treated with the 10:12 
isomer alone showed the largest decrease in viability, with a drop of 48.1% (Fig 4.3). An 
ANOVA test applied to these results showed that there were no significant differences 
between the control and Linoleic acid values or between the Mix and 9:11 values. There 
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was, however, a significant difference between the 9:11 and the 10:12 value, and between 
the Mix, 9:11 and 10:12 values compared to the control (P<0.05) (Table 4.3 Appendix B). 
 
4.2.4 MDA-MB-231 Cells treated with 50µM of CLA for 24 hours. 
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Fig 4.4: MDA-MB-231 Cell viability after treatment with 50µM CLA. Percentage of 
viable cells after 24 hours treatment with 50µM CLA. Average of three experiments, cells 
incubated with Trypan Blue. 
Key: Control – 100% ethanol (equivalent volume); LA – 50µM Linoleic Acid; Mix – 
50µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 50µM c9:t11 isomer alone; 
10:12 - 50µM t10:c12 isomer alone. P<0.05 
 
MDA-MB-231 cells treated with 50µM of Linoleic acid showed a very small increase in 
cell viability (5.1%) compared to the control, this was, however, not significant. The cells 
which were treated with the mix of isomers were on average 61.9% less viable than the 
control, cells treated with the 9:11 isomer alone were on average 57.2% less viable 
compared to the control, and the cells treated with the 10:12 isomer alone showed the 
largest decrease in viability, with a drop of 63.0% (Fig 4.4). Again an ANOVA test 
showed no significance between the Mix, 9:11 and 10:12 values or between the control 
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and Linoleic acid values. There was however a significant difference between the Mix, 
9:11 and 10:12 values and the control (P<0.05) (Table 4.4, Appendix B). 
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4.3: Discussion 
Effect of  Treatment with CLA on Cell Viability. 
 
The viability of both MCF-7 and MDA-MB-231 cells changes significantly with the 
addition of CLA at both 25 and 50µM concentrations. As previously noted ruminant meat 
and milk products contain predominantly the c9:t11 isomer (90%), with the rest being 
made up of the other, less abundant, CLA isomers, including t10:c12. 
 
It is notable that both concentrations of CLA have a greater apoptotic effect on the MDA-
MB-231 cells (oestrogen receptor negative) after 24 hours than on the MCF-7 (oestrogen 
receptor positive) cells. This effect can also be observed with the extraction of protein, the 
MDA-MB-231cells providing, on average, a lower protein yield that the MCF-7 cells. 
 
The cytotoxic effects of CLA’s demonstrated here are somewhat at variance with recently 
published results. In particular Fite et al. showed in 2007 that when MDA-MB-231 cells 
were treated for 48 hours with 40µM of CLA (c9:t11, t10:c12 and a 50:50 mix of the two) 
they exhibited significant cell death (especially in cells treated with the mix and t10:c12 
isomers), but did not show as great a decrease in cell viability as exhibited by the results 
above. The work of Fite et al (2007) showed 30% growth inhibition in the MDA-MB-231 
cells treated with 40µM of the isomer mix, and 35% growth inhibition in cells treated 
with the t10:c12 isomer alone. This compares to the decreases of 61.9%, and 63.0% for 
cells treated with 50µM of the same isomers for 24 hours. Fite showed no significant 
decrease in cell viability for MCF-7 cells treated with CLA, although lower cell viability 
was noted. The greater effect by the CLA on the viability of the MDA-MB-231 cells, 
compared with the MCF-7 cells can also be clearly seen in the current research. There are, 
however, some significant differences between the methods used here and in the work by 
Fite et al. Most importantly Fite et al. used an MTT assay to measure cell viability, 
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compared to the Trypan Blue assay used here. MTT assays are considered to be 
considerably more accurate as they take a reading of optical density, corresponding to cell 
viability. The Trypan Blue assay effectively involves manual counting of viable (white) 
and non viable (blue) cells and coming up with a value for cell viability according to the 
proportion of white to blue cells. As this involves considerable time spent looking down a 
light microscope (with ensuing eye tiredness etc) it is highly prone to human error. 
 
The two CLA isoforms used here are also known to exert a dose dependant effect on the 
cell survival of rat hepatic stellate cells, with the t10:c12 isomer exerting the strongest 
effect. In this case the mix of the two isomers (44%:41% c9:t11: t10:c12) exerted a rather 
smaller effect (80% cell survival compared to around 40% at the highest dose of 180µM) 
that the two isomers did alone, indicating that isomer concentration also has an effect 
(Yun et al. 2008).  
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Investigating a Potential Novel Loading Control for Western Blotting. 
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5. Investigating a Potential Novel Loading Control for Western Blotting. 
5.1 Introduction 
5.1.1 The history of Western Blotting. 
The method for Western Blotting, as set out by Towbin et al. in 1979 (based on a method 
first detailed by Reiser et al. for transferring DNA fragments to a membrane in 1978), is 
still a widely used tool by researchers wishing to detect and quantify proteins of interest in 
cellular extracts. Although it has been slightly revised, and specialised equipment is now 
available, the method has remained largely unchanged in over 20 years. The term 
“Western Blotting” was coined by W. Neal Burnette in 1981. 
 
5.1.2 Western Blotting Techniques. 
The technique involves separating an extract of cellular proteins by sodium dodecyl 
sulphate-Polyacrylamide gel electrophoresis (SDS-PAGE), allowing separation of 
proteins by size by passing a current through the gel matrix or mesh. The separated 
proteins are then transferred to a protein absorbing membrane (PVDF or nitrocelulose) by 
passing a current through the gel, causing the positively charged proteins to move out of 
the gel matrix. Once on the membrane all potential non-specific protein binding sites are 
blocked by a purified, non-reactive protein (often BSA, dehydrated milk preparations, or 
Casein) and a primary antibody to the protein of interest is added. A generalised 
fluorescently labelled secondary antibody, usually from the immunoglobulin super-
family, is allowed to attach to the primary antibody, and the fluorescence produced 
measured. The secondary antibody is usually tagged with the Horseradish Peroxidase 
enzyme (HRP), which allows fluorescence to be produced. The enzyme is extracted from 
the roots of the Horseradish plant (Armoracia rusticana, syn. Cochlearia armoracia) by 
affinity chromotography, and its high specificity and versatility are the main reason it is 
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used as a popular research tool. HRP exerts its effect by cleavage of various substrates to 
produce either a colorimetric, or a fluorescent signal. In the case of Western Blotting the 
HRP enzyme is used to catalyse, and enhance the natural oxidation of luminol in the 
presence of Hydrogen Peroxide. The areas of enhanced chemiluminescence around the 
high concentration of the HRP enzyme show up as dark bands on the final picture. 
Measurements are usually calculated as the intensity of signal per mm2, the theory being 
that the more protein bound to the membrane, the greater the amount of antibody bound, 
and therefore the greater the signal. The intensity of the bands is measured using a 
sensitive computer software package, capable of measuring the density of individual 
pixels in a selected area. Using this software the band of interest is selected manually, and 
the computer works out an average density according to the size of the area selected, and 
the intensity of the pixels. This average intensity per mm2 can then be compared to the 
value for the control. 
 
5.1.3 The Use of Loading Controls in Western Blotting.  
Usually a second protein is also selected to act as a loading control or housekeeping 
protein in order to allow any results to be standardised and analysed with a degree of 
confidence as to their relevance having eliminated errors due to differences in loading 
between wells. Several popular antibodies are sold by a number of different specialist 
antibody suppliers as “loading controls”, the most notable of these being ß-actin. ß-actin 
is very widely used as a loading control, however in 2006 Dittmer and Dittmer suggested 
that at higher protein loads, and over longer incubation times it is much less sensitive to 
changes in protein loading, due to its high cellular abundance. ß-actin is also only found 
in the soluble protein fraction; not in the insoluble membrane fraction meaning that it is 
unsuitable for detecting protein loading for membrane bound proteins. Currently there is 
 95 
no ubiquitously expressed, non-modifiable membrane- bound protein which is considered 
suitable for general use as a loading control. 
 
5.1.4 Claudin-3 
Claudin-3 is a member of the Claudin super family, first identified by Furuse et al in 
1998. The Claudins are a family of 23 membrane bound proteins, which are found in 
tissue specific conformations throughout the body. They are part of an important tight 
junction complex (Miyoshi et al. 2005), forming the backbone on which the complex is 
based. Claudin-3 is found in cells throughout the body (Katahira et al. 1997), and its 
increased expression has been observed in a number of different cancer types (Morin, 
2005). Claudin-3 has been shown to be present in a number of different cancer cell lines, 
including MCF-7 and MDA-MB-231, and to be unaffected by the addition of conjugated 
linoleic acid isomers (Murphy et al. 2006). As yet no research has been done into the 
effect which the omega-3 fatty acids EPA and DHA have on Claudin-3 in any cell line. 
 
5.1.5 Linoleic acid and CLA. 
As previously stated (Chapter 1, page 8) Linoleic acid (LA) is a common fatty acid found 
in a few plant species and in ruminant meat and milk products, LA may be modified to 
form various different isomers, including conjugated linoleic acids (CLA’s). CLA’s are a 
group of isomers of LA with conjugated double bonds along the fatty acid chain, the main 
form being the cis-9:trans-11 isomer (Ha et al. in 1987). As with many other fatty acids 
CLA’s are of great interest to researchers due to their apparent chemo-protective and anti-
adiposity qualities (Wang et al. 2004, Dauchy et al. 2004, Belury, 2002, Kohno et al. 
2004, Kohno et al. 2004). 
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In MCF-7 breast cancer cells, CLA isomers are known to induce apoptosis, and to slow 
growth and metastasis of implanted mammary tumours (Majumder et al. 2002, Liu et al. 
2004, Chujo et al. 2003). CLA’s are also known to up- or down- regulate a wide spectrum 
of proteins, including PPAR and PKC, within many different cancer cell lines. 
 
5.1.6 Experimental Aims 
The aims of this experiment are to determine whether Claudin-3 can be considered as an 
effective loading control for membrane bound proteins extracted from CLA treated MCF-
7 cells, and to determine if Claudin-3 shows a greater degree of sensitivity to changes in 
loading than Ponceau Red staining. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 97 
5.2  Results 
Claudin-3, ß-Actin and Ponceau Red, a Comparison. 
 
5.2.1 ß-actin in cytosolic and membrane bound protein fractions. 
 
Figure 5.1: ß-actin in MCF-7 cytosolic and membrane bound protein fractions. 
MCF-7 cells were treated with 25µM CLA isoforms.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. PKC alpha is included to verify loading. 
 
Protein extracted using the Calbiochem ProteoExtract Native Protein Extraction kit 
exhibited detectable levels of ß-actin expression only in the cytosolic protein fraction of 
MCF-7 cells (Figure 5.1). PKC α, a protein known to be present in both fractions was 
used as a control. Optimisation experiments showed that the PKC isoforms were detected 
with enough strength and clarity to enable accurate measurement of band density at 40µg 
of protein; this was determined by a standard Lowry assay. 
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5.2.2 Claudin-3 expression in membrane bound protein fractions. 
 
Figure 5.2: Expression of Claudin-3 and ß-actin in total protein extracts. MCF-7 
cells, treated for 48 hours with 25µM CLA.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone (initial results, not fully optimised, but indicative of 
separation). 
 
 
Initial experiments showed that Claudin-3 was well expressed in the membrane fraction of 
MCF-7 cells (Figure 5.2). Total protein from MCF-7 cells treated with CLA and LA 
showed detectable levels of Claudin-3 and Beta-actin with sufficient band strength and 
clarity to enable an accurate measurement of band density at 40µg of protein (determined 
by a standard Lowry assay).  
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5.2.3 Ponceau Red staining of membrane bound protein. 
A. 
 
B.  
 
Figure 5.3: Determining protein loading by Ponceau R staining. A: Staining pattern of 
10µg, 20µg, 30µg, 40µg, 50µg and 60µg of protein, blocked in 5% non- fat milk and 
TBS-T and stained with 0.1% Ponceau red solution for 5 minutes. B: Density of the 83kD 
to 47.5kD area expressed as a percentage of the 10µg lane, data obtained is for three 
independent experiments (one sample per experiment). P<0.05 
 
Ponceau red stained all proteins adhering to a PVDF membrane (Figure 5.3.A). The 
density of the stained band can be read from anywhere on the membrane, the area 
between 83 and 47.5 KD being an arbitrary choice.  Lanes loaded with 10- 60µg of total 
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protein and stained with Ponceau Red showed increasing band density, although the 
higher protein amounts showed a decreased sensitivity to changes into the amount of 
protein loaded (Figure 5.3.B). 
 
5.2.4 Comparing Claudin-3 and ß-actin. 
 
Figure 5.4: Analysis of band density for ß-actin and Claudin-3. As a percentage of the 
density of the control band. Data represents the results obtained from three independent 
experiments (two samples per treatment). P<0.05 
 
Neither the Claudin-3, nor the ß-actin exhibited an increase or decrease of more than 4.7% 
of the control value for any treatment. The difference between the unadjusted Claudin-3 
and ß-actin values for all five treatments did not exceed 6.3% of the control (treatment 
with the t10:c12 isomer alone), and showed an average of 3.2% across both samples 
(figure 5.4). Apart from the t10:c12 isomer treatment the difference between the values 
for Claudin-3 and ß-actin is largely constant, although Claudin-3 exhibited slightly 
elevated levels (around 2.2% more than ß-actin). None of these figures showed any 
statistical significance when treated with a standard Mann-Whitney paired t test. 
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5.2.5 Comparing Ponceau Red and ß-actin. 
 
Figure 5.5: Band density for ß-actin and Ponceau Red staining. As a percentage of the 
density of the control band. Data represents the results obtained from three independent 
experiments (two samples per treatment). P<0.05 
 
The average difference in un-adjusted density as a percentage of the control for the 
Ponceau Red and ß-actin was 3.7%, with the value not exceeding 6.3% (treatment with 
the 9:11 isomer alone, figure 5.5). Neither the Ponceau Red nor the ß-actin densities 
exhibited an increase or decrease of more than 4.8% of the control value and none of the 
figures showed any statistical significance. The values showed very little constancy 
although the Ponceau Red values are further from the control than the values for the ß-
actin.  
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5.2.6 Comparing Claudin-3 and Ponceau Red. 
 
Figure 5.6: Band density for Claudin-3 and Ponceau Red staining. As a percentage of 
the density of the control band. Data represents the results obtained from three 
independent experiments. P<0.05 
 
The average difference in un-adjusted density as a percentage of the control for the 
Ponceau Red and Claudin-3 was 6.9% (figure 5.6), almost double the equivalent values 
for either density compared to the ß-actin. The largest single difference, for the treatment 
with the 9:11 isomer alone was 8.7%, again greater than the difference in values for either 
method compared to ß-actin. None of the figures show any statistical significance. Despite 
the differences neither the Claudin nor the Red Ponceau exhibited an increase or decrease 
of more than 4.8% of the control value for any treatment. Apart from the values for the 
linoleic acid treatment the difference between the values was reasonably constant. 
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5.3. Discussion 
Claudin-3 and its suitability as a loading control. 
 
The expression of the Claudin-3 protein does not appear to change significantly, if at all, 
with the five different treatments used. As the two CLA isomers used are those most 
commonly explored, due to their relative natural abundance or known beneficial effects 
on disease processes. It is, therefore, likely that the relative expression of this protein 
would remain unchanged in cells treated with a more natural mix of isomers. This is 
because milk and ruminant meat products contain a predominance of the c9:t11 isomer 
(90%). The c9:t11 isomer is the most efficiently produced positional isomer of LA by 
microbial anaerobic fermentation and bio-hydrogenation in the ruminant gut. The range of 
other isomers of CLA produced in this way make up the remaining 10%, although this 
may be altered by a change to the diet of the ruminant. It is also noteworthy that the 
c9:t11 and the t10:c12 isomers generally have the greatest impact on the growth and 
apoptosis of cells and tumours. Therefore, they are in much greater use, and exhibit much 
greater popularity as commercial supplements and as research tools. 
 
The expression of ß-actin in the total protein extracts, but not in the membrane fraction 
extracts, was expected, with beta actin being found only in the cytosol in most cell types. 
This suggests that ß-actin is not a suitable loading control for all experiments, especially 
those looking only at active or inactive proteins in the cell membrane.  
 
The Ponceau Red staining pattern on the PVDF membranes, as expected, showed 
differences only where different amounts of protein were loaded. Two issues must be 
addressed when considering Ponceau Red as a loading control; the first is that the dye has 
a relatively small effective range since protein loading of greater than 30µg resulted in 
reduced sensitivity of the stain. According to experiments performed by Yonan et al. at 
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protein concentrations <0.5µg Ponceau Red does not detect proteins on PVDF 
membranes, although the stain is slightly more sensitive on Nitrocellulose membranes. 
The second factor is the relative difficulty in getting a constant staining pattern across the 
full surface of the membrane, and the highly water soluble properties of the dye are issues 
which must be addressed when using Ponceau Red as a quantitave stain. The current, and 
highly sensitive computer hardware and software used to measure quantative staining uses 
only a small section of the area on which the protein is loaded, therefore any spots, over 
rinsed areas or accidental watermarks can cause a false positive or false negative result. 
As a qualitative stain to check for transfer of protein it has remained a popular technique 
due to its reversibility and versatility. 
 
As a reliable general loading control for membrane bound proteins, Claudin-3 may still be 
said to be unproven as there has been no other data in the literature regarding its usage in 
this manner. The present results show that, as a loading control for CLA treated MCF-7 
breast cancer cells, Claudin-3 may provide a higher degree of accuracy as a housekeeping 
protein (as examined in section 5.1.3, P94) in the study of membrane bound proteins than 
Ponceau red staining. 
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Chapter 6 
Modulation of Protein Kinase C (PKC) isoforms in MCF-7 Cells, when 
treated with Conjugated Linoleic acid (CLA) and Linoleic Acid (LA) 
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6. Modulation of Protein Kinase C (PKC) isoforms in MCF-7 Cells, when treated 
with Conjugated Linoleic acid (CLA) and Linoleic Acid (LA) 
 
6.1 Introduction 
6.1.1 Cancer incidence and survival 
Breast cancer accounts for 15% of the total cancer burden in the UK, this relates to 30% 
of all new cancers detected in women. The five year survival rates for women with breast 
cancer currently stand at circa 77%, due largely to improvements in chemotherapeutic 
drugs (Cancer Research UK, 2001). Hormone receptor positive breast cancer is 
preferentially treated with Tamoxifen (Taylor and Taguchi, 2005). Within the past few 
years, however, many people have been turning towards complimentary therapies, in 
particular nutritional supplements, to help treat breast cancer in tandem with conventional 
medical techniques. There is some evidence to suggest that some of these nutritional 
therapies, in particular the well publicized “five-a-day” fruit and vegetable initiative, do 
actually increase the survival rates and reduce the risk of recurrence of breast cancer 
(Joshipura et al. 2001). 
 
6.1.2. Fatty acids and cancer  
Linoleic acid is found in a few plant species and in ruminant meat and milk products, as 
previously noted LA may be modified in many ways to form various positional isomers, 
including conjugated linoleic acids (CLA’s). Edible oils and ruminant milk and meat 
products make up the main intake of CLA by humans, although consumption of these 
varies. In humans, dietary CLA can be detected in the plasma and lymph fluid and is 
known to have a positive effect on various conditions, including diabetes, obesity, 
arthrosclerosis and some cancers (Wang and Jones, 2004, Belury, 2002). It has already 
been established that CLA has an anti proliferative effect on androgen sensitive prostate 
 107 
cancer cells, and both oestrogen receptor positive and negative breast cancer cell lines 
respond in a similar manner (Song et.al 2004, Wang et.al 2008 and Miglietta et.al 2006). 
 
6.1.3 Mechanisms affected by CLA 
Various cancer cell lines exhibit cellular apoptosis when treated with isomers of CLA in 
vitro, similarly tumours, either induced or grafted in animal models, especially rats, show 
a decrease in size and weight when the diet is supplemented with CLAs (Dugram and 
Fernandes, 1997, Song et al. 2004, Field and Schley, 2004, and Bocca et al. 2006). The 
reasons for increased apoptosis are unclear. However, CLA has been shown to influence 
the expression of various proto-oncogenes, including p53, p21 and Bcl-2 (Majumder et al. 
2002), all of which have pro-apoptotic properties.  
 
6.1.4. PKC-isoforms and cancer 
There are definite links between cellular apoptosis and the presence of the various Protein 
Kinase C (PKC) isoforms. Differential expression of PKC isoforms in various tissue types 
has been investigated, with certain isoforms appearing abundantly in different cell types, 
this suggests unique functions are performed by each isoenzyme (Ford et al. 1995, Ryer et 
al. 2005, and Mischak et al. 1993). 
 
6.1.5 Experimental Aims 
As yet very little or nothing has been reported about the effect of CLA, on the PKC 
profile of MCF-7 cells. The current research aims to study the effect of CLA (25 and 
50µM) on the three PKC isoforms α, δ, and ι using protein extraction from cytosolic and 
membrane fractions and western blotting techniques. 
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6.2 Results 
PKC Activation in MCF-7 Cells After Treatment With CLA. 
 
6.2.1 PKC α 
6.2.1.1 Treatment of MCF-7 Cells With 25µM CLA. 
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Figure 6.1: Effect of CLA’s on PKC α. MCF-7 cells treated with 25µM CLA isoforms 
or 25µM DAG. ß-actin was used to verify loading in cytosolic protein samples, Claudin-3 
was used to verify loading in membrane bound protein samples. Data are from three 
independent experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 (*) 
 
 
Membrane abundance of active PKC α showed an increase of 8.6% and 12.4% (24 hours, 
25µM LA or 50:50 mix treatment, Fig 6.1). With LA treatment the inactive cytosolic PKC 
α was reduced by 7.5%, while with the mix of isomers PKC α was decreased by 2.2%. 
Cells treated with the individual c9:t11 and t10:c12 isomers at 25µM concentrations 
showed a decrease in membrane bound PKC α by 6.3% and 20.9% respectively. A 
corresponding increase in the amount of inactive PKC α was detected in the cytosol. Only 
the result for the membrane bound t10:c12 treatment alone shows any statistical 
significance when treated with a standard Mann-Whitney paired t test. The membrane 
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abundance of active PKC α exhibited an increase of 40.7% in cells treated with 25µM 
DAG, the comparative decrease in cytosolic PKC α was 23.0%, both of these results show 
statistical significance. 
 
6.2.1.2 Treatment of MCF-7 Cells With 50µM CLA. 
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Figure 6.2: Effect of CLA’s on PKC α. MCF-7 cells treated with 50µM CLA isoforms. 
ß-actin was used to verify loading in cytosolic protein samples. Claudin-3 was used to 
verify loading in membrane bound protein samples. Data are from three independent 
experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 50µM Linoleic Acid; Mix – 
50µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 50µM c9:t11 isomer alone; 
10:12 - 50µM t10:c12 isomer alone. P<0.05 
 
Membrane abundance of active PKC α was decreased after treatment for 24 hours with 
50µM of the individual c9:t11 and t10:c12 isomers and the 50:50 mix of isomers (Fig 
6.2). The 50:50 mix showed a non significant decrease of the active PKC α (6.8%) while 
causing a slight increase of the inactive cytosolic PKC α (11.7%). The c9:t11 and t10:c12 
isomers both caused significant decreases of active PKC α by 17.7% and 31.4% 
respectively. A significant increase (22.2%) of cytosolic PKC α was observed in cells 
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treated with the t10:c12 isomer (50 µM) alone, however with the c9:t11 isomer a non 
significant decrease of 4.2% in inactive PKC α was obtained. The membrane abundance 
of PKC α in cells treated for 24 hours with 50µM of LA showed a very small increase 
(0.8%), while the cytosolic PKC α was decreased by 4.6%, neither of these results are 
statistically significant. Treatment with 50µM DAG however exhibited significant 
increase (50.2%) in the membrane bound protein PKC α. The abundance of cytosolic 
PKC α on the other hand, showed an insignificant decrease (9.6%) 
 
6.2.2 PKC δ 
6.2.2.1 Treatment of MCF-7 Cells With 25µM CLA. 
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Figure 6.3: Effect of CLA’s on PKC δ. MCF-7 cells treated with 25µM CLA isoforms 
or 25µM DAG. ß-actin was used to verify loading in cytosolic protein samples, Claudin-3 
was used to verify loading in membrane bound protein samples. Data are from three 
independent experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 
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No statistical significance was observed for any of the four 25µM treatments used when 
PKC δ was detected in either its inactive or active forms. Both the isomer mix and the 
t10:c12 treatment alone showed a slight decrease (16.4% and 11.2% respectively, Fig 6.3) 
in the amount of membrane bound PKC δ, and the inactive protein in cells treated with the 
mix of isomers exhibited a decrease of 9.8%. An even smaller change in membrane bound 
PKC δ, this time an increase, was observed in the cells treated with the c9:t11 isomer. 
2.6% more active protein was seen, the decrease in the cytosolic PKC δ was only 0.9%. 
The cells treated with LA exhibited a 0.4% decrease in PKC δ concentration; however, 
the cytosolic fraction showed a larger decrease of 16.0%. In cells treated with 25µM DAG 
these experiments exhibited a small, but not significant increase in the membrane 
abundance of active PKC δ (1.2%), equally the decrease in cytosolic PKC δ was not 
significant (12.9%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112 
6.2.2.2 Treatment of MCF-7 Cells With 50µM CLA. 
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
120.00%
140.00%
160.00%
180.00%
Con LA Mix 9:11 10:12 DAG
Treatment
P
r
o
te
in
 c
o
n
c
e
n
tr
a
ti
o
n
 a
s
 a
 p
e
r
c
e
n
ta
g
e
 o
f 
th
e
 c
o
n
tr
o
l 
v
a
lu
e
.
Cytosolic Protein
Membrane Bound Protein
 
Figure 6.4: Effect of CLA’s on PKC δ. MCF-7 cells treated with 50µM CLA isoforms. 
ß-actin was used to verify loading in cytosolic protein samples. Claudin-3 was used to 
verify loading in membrane bound protein samples. Data are from three independent 
experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 
 
Membrane abundance of active PKC δ was increased in cells treated for 24 hours with 
50µM LA, the 50:50 mix of the isomers, and the c9:t11 and t10:c12 isomers alone (Fig 
6.4). With the LA treatment the active PKC δ increased by 31.8%, while the inactive 
cytosolic PKC δ decreased by 1.5%. The cells treated with the 50:50 mix of isomers 
showed a significant increase in the active, but not the inactive PKC δ, 54.7% and 4.5% 
respectively. The individual c9:t11 and t10:c12 isomers at 50µM concentrations showed a 
significant increase of 46.8% (c9:t11) and 33.5% (t10:c12) of active PKC δ, there was 
also a corresponding increase in the amount of inactive PKC α detected in the cytosol of 
3.6% (c9:t11) and 23.1% (t10:c12). The membrane abundance of active PKC δ exhibited 
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an increase of 8.1% in cells treated with 50µM DAG, the comparative decrease in 
cytosolic PKC δ was 21.8%, neither of these results showed statistical significance. 
 
6.2.3 PKC ι 
6.2.3.1 Treatment of MCF-7 Cells With 25µM CLA. 
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Figure 6.5: Effect of CLA’s on PKC ι.  MCF-7 cells treated with 25µM CLA isoforms 
or 25µM DAG. ß-actin was used to verify loading in cytosolic protein samples. Claudin-3 
used to verify loading in membrane bound protein samples. Data are from three 
independent experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 
 
The concentration of membrane bound PKC ι was increased in all four treatments (Figure 
6.5), with this increase showing statistical significance in the cells treated with the LA, 
isomer mix and t10:c12 alone (30.9%, 32.8% and 26.2%). The cells treated with the 
c9:t11 isomer alone also exhibited an increase of 20.9%, but this was not found to be 
significant. The corresponding concentration of inactive PKC ι in the cytosol showed a 
reduction in all four treatments, again the LA, isomer mix and t10:c12 alone showed 
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statistical significance. The results for PKC ι in membrane and cytosolic protein fractions 
when treated with 25µM DAG are not statistically significant, showing an increase of 
2.3% and 6.8% respectively. 
 
6.2.3.2 Treatment of MCF-7 Cells With 50µM CLA. 
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Figure 6.6: Effect of CLA’s on PKC ι. MCF-7 cells treated with 50µM CLA isoforms or 
25µM DAG. ß-actin was used to verify loading in cytosolic protein samples, Claudin-3 
used to verify loading in membrane bound protein samples. Data are from three 
independent experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 
 
Membrane abundance of active PKC ι was increased in cells that had been treated for 24 
hours with 50µM of the LA, 50:50 mix, c9:t11 and t10:c12 isomers respectively (Fig 6.6). 
With LA treatment the inactive cytosolic PKC ι was reduced by 1.5% while the active 
PKC ι showed the smallest increase (23.4%). The cells treated with the 50:50 mix at the 
50µM concentration showed a significant increase of 16.0% in the amount of inactive 
PKC ι, a corresponding increase of 39.0% in the membrane bound PKC ι was also 
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observed. Cells treated with the c9:t11 isomer alone demonstrated a 0.2% decrease in 
inactive PKC ι and a 43.1% increase in active PKC ι. Cells treated with the t10:c12 
isomer alone showed a 4.0% increase in inactive PKC ι and a 42.5% increase in active 
PKC ι.  None of these results showed any statistical significance. The membrane 
abundance of active PKC ι exhibited a decrease of 1.8% in cells treated with 50µM DAG, 
the comparative decrease in cytosolic PKC ι was 5.2%, neither of these results show 
statistical significance.  
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6.3 Discussion  
Effects of Treatment With CLA in Oestrogen Receptor Positive Cells on Abundance of 
Active and Inactive PKC.  
 
There have been several studies, both in vivo, and in vitro which appear to indicate that 
CLA has the potential to suppress the development and proliferation of various types of 
cancer cells, including breast cancer (most recently, Wang et al. 2008). While some steps 
have been made to elucidate the mechanism by which CLA exerts these effects much of 
its action upon cell signalling pathways is still unclear. In this study however the effects 
of CLA upon the regulation of various PKC isoforms in the oestrogen receptor positive 
breast cancer cell line MCF-7 have been clearly shown.  
 
It has already been demonstrated that CLA has a pro-apoptotic effect upon prostate cancer 
LNCaP cells (Song et. al 2004), and this study shows evidence of a similar effect by CLA 
in MCF-7 cells.  
 
Membrane association of PKC is indicative of activation, through allosteric activation, by 
diacylglycerol (DAG) or by negatively charged phospholipids. The presence of 
phosphatidylserine (PS) is required by the typical and novel isoforms, and 
phosphatidylethanolamine or 3-phosphoinositides (PIP3) by the atypical PKCs.  
 
The incubation of 25 and 50µM of CLA with MCF-7 cells in vitro has a significant pro-
apoptotic effect, with 50µM of the cis-9:trans-11 isomer alone causing a 39.4% decrease 
in cell viability, as measured by Trypan blue assay. Thus it would be expected that these 
changes would be associated with changes to activation of the three PKC isoforms studied 
so far. 
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6.3.1 Effect of CLA on PKC α Expression 
Active PKC α has been implicated in both anti-apoptotic and anti-proliferative effects, in 
various cell lines (Dempsey et. al 2000), however there is also strong evidence that it 
exerts a pro-apoptotic effect in LNCaP cells, due to persistent activation (Powell et al. 
1996). Generally PKC α activation is associated with increased cell growth and survival 
in several cell lines, including MCF-7 (Ways et al. 1996). In this study it was shown that 
PKC α  activation was decreased with both 25 and 50µM cis-9:trans-11 and trans-10:cis-
12 isomers of CLA treatment. This concurs with the findings of Song et al. (2004), who 
observed a similar effect, although the decrease was more pronounced in PKC α 
activation after 24 hours treatment with 25 or 50µM of the individual isomers in the 
LNCaP prostate cancer cell line. It is noteworthy that, while the decrease in PKC α 
activation in the MCF-7 cells lines used in this experiment is greater after treatment with 
50µM of CLA, in the LNCaP cells this decrease was greater after treatment with 25µM. 
In comparison to the behaviour of the LNCaP cells the changes in PKC α activation in 
MCF-7 cells are much less dramatic, and much less significant. After 24 hours treatment 
with the 50:50 mix of the two isomers, at a concentration of 25µM, the activated PKC α 
being expressed by the cells appeared to increase. The fact that the two isomers separately 
at the same concentration both cause a significant decrease in active PKC α raises 
speculation that this result, with the Mix, is an anomaly, especially given that at 50µM of 
CLA the isomer mix causes a non significant decrease in PKC α activation. In LNCaP 
cells however this pattern is repeated, although there is a slight decrease in active PKC α 
rather than a slight increase (Song et al. 2004). 
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6.3.2 Effect of CLA on PKC δ Expression 
PKC δ activation is believed to mediate opposing effects to PKC α activation (Dempsey 
et. al 2000). Many of these effects are believed to be due to the action of activated PKC δ 
as a substrate for interleukin-1 converting enzyme (ICE) like proteases; also known as the 
“Executioner caspases”, specifically caspase-3 (Basu, 2003). In general, PKC δ activation 
increases pro-apoptotic events, by cleavage from its auto-inhibitory domain, and 
subsequent migration to cell and mitochondrial membranes (Basu, 2003). Down-
regulation of PKC δ has been linked to tumour progression, while up-regulation is known 
to inhibit the progression of the cell cycle (Mischak et al. 1993). There is however a 
suggestion that, in the presence of tamoxifen, the PKC δ pathway is a major alternative 
pathway for cell growth in MCF-7 cells (Nabha et al. 2005). 
 
In this study a significant increase in PKC δ activation was observed after treatment with 
50µM of the 50:50 isoform mix, the cis-9:trans-11 and the trans-10:cis-12 isomers alone. 
Equally an increase in the amount of cytosolic PKC δ was also seen, suggesting that any 
increase may not be due solely to translocation to the cell membrane, but may in fact have 
an altered gene expression or a genetic component as well. This increase is similar to the 
activity pattern observed by Song et al., in the LNCaP cell line. However, with the PKC α 
the increase is several orders of magnitude smaller in the LNCaP. In LNCaP cells the cis-
9:trans-11 isomer alone appears to exert the greatest effect on PKC δ activation, with the 
trans-10:cis-12 isomer and the 50:50 mix of the two exerting a smaller effect. In the 
MCF-7 cell line we see what appears to be the opposite happening, the 50:50 mix is 
exerting the greatest effect on PKC δ activation, while the cis-9:trans-11 and the trans-
10:cis-12 isomers individually exert smaller effects.  
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At concentrations of 25µM, the situation is different, rather than increasing the activation 
of PKC δ it appears that, unlike the LNCaP cells, lower concentrations of the 50:50 mix, 
and the trans-10:cis-12 isomer alone CLA actually decrease active PKC δ. A small 
increase in active PKC δ is observed after treatment with 25µM of the cis-9:trans-11 
isomer, but this was not significant.  
 
6.3.3 Effect of CLA on PKC ι Expression 
PKC ι is a marker of poor prognosis, and increased cell survival in many different types 
of cancer, including, non small cell lung cancer, ovarian cancer and prostate cancer (Lu et 
al. 2001, Eder et al. 2005; Win and Acevedo-Duncan, 2008). PKC ι resides on 
chromosome 3q26; amplification of this region is common in non small cell lung cancer 
(predominantly squamous cell carcinoma), and ovarian tumours. 3q26 amplification has 
also been observed in cervical, and oesophageal tumours, suggesting that PKC ι may play 
an even more important role in cancer biology than previously thought (Fields et al. 
2007). It is actually the first of the PKC isoforms to be shown to possess the three singular 
characteristics of a cancer gene (i. critical to cancer cell biology, ii. activated in primary 
tumours and, iii. targets for tumour specific genetic alterations, Regala et al. 2005). In 
breast cancer cells, recent research suggests that the over expression of PKC ι increases 
the invasiveness of breast cancer cells (progression from ductal carcinoma in stitu to 
invasive ductal carcinoma), although no correlation with other prognostic indicators (i.e 
oestrogen receptor status, progesterone receptor status, HER2 etc) was found (Kojima et 
al. 2008). Results from immunohistochemistry staining for PKC ι showed an increase 
corresponding to the severity of the pathological type of tumour, although there was no 
apparent correlation between PKC ι presence and tumour grade. This suggests that the 
active protein expression for PKC ι should decrease after treatment with the various CLA 
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isoforms. The results gained for both the 25 and the 50µM treatments indicate that this is 
not the case; although neither do they display any real significance. The work of Song et 
al. in LNCaP cells showed a clear decrease in active, membrane bound PKC ι after 
treatment with CLA, and significantly increased cytosolic abundance of inactive PKC ι. 
This data, from Song et al. is consistent with the increased apoptosis observed after 
treatment with CLA, as PKC ι expression is a potent factor in cell survival. Explanations 
for the increased active PKC ι levels observed in MCF-7 cells in the present study are 
unclear, but would indicate an adverse effect by CLA on MCF-7 cells. This is country to 
the cytotoxic effects of CLA on MCF-7 cells demonstrated in chapter 4. The aspect of 
marked differences in PKC isoform expression pattern in different cell lines on exposure 
to CLA requires further evaluation. 
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Chapter 7 
Modulation of Protein Kinase C (PKC) isoforms in MDA-MB-231 Cells, 
when treated With Conjugated Linoleic acid (CLA) and Linoleic Acid 
(LA) 
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7. Modulation of Protein Kinase C (PKC) isoforms in MDA-MB-231 Cells, when 
treated with Conjugated Linoleic acid (CLA) and Linoleic Acid (LA) 
 
7.1 Introduction 
Oestrogen receptor negative breast cancers make up only 25% of the total number of new 
breast cancers detected every year. The MDA-MB-231 breast cancer cell line is an 
accepted model for oestrogen, and progesterone receptor negative breast cancers. The cell 
line was first obtained in 1973 from a pleural effusion of a tumour for which the patient 
had already undergone a mastectomy and radiotherapy. MDA-MB-231 cells display an 
aberrant morphology, forming spindle shaped epithelial like cells. 
 
Oestrogen and its various isoforms are best known for the effects they have upon the 
female reproductive system, among other functions they play a large part in controlling; 
ovulation, pregnancy, childbirth and lactation. Oestrogen is also a known promoter of cell 
growth and survival, binding to oestrogen receptors (ER’s). The presence of oestrogen 
receptors is known to confer an increased likelihood of disease free survival, and 
increased 5 year survival on patients, while oestrogen receptor negative tumours have a 
higher rate of recurrence, regardless of the many factors which have been found to change 
risk of recurrence in oestrogen receptor positive tumours (Knight et al. 1977). There are 
several potential mechanisms by which previously ER positive cells may loose the ability 
to express ER receptors, these include long term oestrogen withdrawal (as caused by 
menarche, especially early menarche, or long term use of hormonal contraceptives, Santen 
et al. 2002) and hypoxia (Stoner et al. 2002). ER expression may also be suppressed by 
the up regulation of Mitogen Activated Protein Kinase (MAPK) (Creighton et al. 2006). It 
has also been shown that cells which have lost the ability to express ER receptors can be 
persuaded to re-express them by inhibition of hyperactive MAPK expression. This 
inhibition leads to restoration of the ER expression and the associated sensitivity of the 
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cells to anti-oestrogen therapies, without this anti-oestrogen therapies, used to treat 
oestrogen receptor positive breast cancer (for which the MCF-7 cell line is a model), are 
mostly ineffective against oestrogen receptor negative tumours (Bayliss et al. 2007). 
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7.2 Results  
PKC Activation in MDA-MB-231 Cells after Treatment with CLA  
 
7.2.1 PKC α 
7.2.1.1 Treatment of MDA-MB-231 Cells With 25µM CLA. 
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Figure 7.1: Effect of CLA’s on PKC α. MDA-MB-231 cells treated with 25µM CLA 
isoforms or 25µM DAG. ß-actin was used to verify loading in cytosolic protein samples, 
Claudin-3 was used to verify loading in membrane bound protein samples. Data are from 
three independent experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 (*) 
 
 
The abundance of active PKC α in cells treated for 24 hours with 25µM of the 50:50 
isomer mix, the c9:t11 isomer alone and the t10:c12 isomer alone showed a general 
decrease (Figure 7.1). Treatment with the isomer mix produced only a small decrease in 
active PKC α (1.2%), however treatment with the c9:t11 and the t10:c12 isomers 
individually produced a much greater, and highly significant decrease (25.3% and 35.7% 
respectively). All four treatments showed a small, and non significant decrease in the 
amount of inactive PKC α present in the cytosol. Treatment with LA produced a 
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significant increase in the amount of active PKC α in the membrane bound fraction, 
14.5%.  
 
Treatment with 25µM DAG for 24 hours showed a significant increase in active PKC α 
(49.3%) and also a significant decrease in inactive PKC α (14.8%). 
 
7.2.1.2 Treatment of MDA-MB-231 Cells With 50µM CLA. 
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Figure 7.2: Effect of CLA’s on PKC α. MDA-MB-231 cells treated with 50µM CLA 
isoforms. ß-actin was used to verify loading in cytosolic protein samples. Data are from 
three independent experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 
 
Membrane abundance of active PKC α was increased by 5.1%, 21.7% and 31.3% in cells 
treated for 24 hours with 50µM of the 50:50 mix and the c9:t11 and t10:c12 isomers 
separately (Figure 7.2). With the LA treatment the active PKC α was slightly decreased 
by 2.6%. The cells treated with the mix and the c9:t11 isomer at 50µM concentrations 
showed a non significant decrease in inactive PKC α, 4.2% (mix) and 5.7% (c9:t11) 
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respectively. The t10:c12 treated cells showed a significant decrease in the amount of 
inactive PKC α (6.9%). The results for the active PKC α in cells treated with the c9:t11, 
and t10:c12 isomers alone showed statistical significance. Treatment with 50µM DAG for 
24 hours produced an increase in active PKC α by 21.4% and a decrease in inactive PKC 
α by 9.3%. Neither of which is significant. 
 
7.2.2 PKC δ 
7.2.2.1 Treatment of MDA-MB-231 Cells With 25µM CLA. 
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Figure 7.3: Effect of CLA’s on PKC δ. MDA-MB-231 cells treated with 25µM CLA 
isoforms or 25µM DAG. ß-actin was used to verify loading in cytosolic protein samples, 
Claudin-3 was used to verify loading in membrane bound protein samples. Data are from 
three independent experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 
 
Treatment with 25µM of CLA produced a general decrease in active PKC δ across all the 
isoforms (Figure 7.3). 25µM of LA caused a decrease of 5.0% and treatment with the 
50:50 isomer mix caused a decrease of 10.4%, neither of which is significant. Treatment 
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with the c9:t11 and t10:c12 isomers alone showed significant decreases in active PKC δ, 
28.0% for the c9:t11 isoform, and 33.4% for the t10:c12 isoform. Inactive PKC δ was 
largely unchanged across all the treatments, with the LA, 50:50 mix and c9:t11 isomer 
exhibiting no significant change in inactive PKC δ (2.9% decrease, 0.8% increase and a 
1.3% decrease respectively). The t10:c12 isoform exhibited a significant, although 
comparatively small decrease of 8.2%.  
 
Treatment with 25µM DAG for 24 hours produced an increase, although not a significant 
one of 5.6% in active PKC δ. The decrease in inactive PKC δ (13.5%) however is 
statistically significant. 
 
7.2.2.2 Treatment of MDA-MB-231 Cells With 50µM CLA. 
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Figure 7.4: Effect of CLA’s on PKC δ. MDA-MB-231 cells treated with 50µM CLA 
isoforms. ß-actin was used to verify loading in cytosolic protein samples. Data are from 
three independent experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 
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Cells treated for 24 hours with 50µM of the c9:t11 and t10:c12 isomers alone exhibited a 
significant increase in membrane bound PKC δ, of 13.4% and 13.1% respectively. Cells 
treated with 50µM of the 50:50 isomer mix showed only a small increase (2.4%) in active 
PKC δ which fails to be statistically significant (Figure 7.4). Similarly, treatment with LA 
also led to a small, insignificant increase in active PKC δ (6.3%). 
 
Decreases in inactive PKC δ also fail to exhibit statistical significance, it was notable that 
inactive PKC δ decreased for all the treatments, but was not proportional to active PKC δ.  
Treatment with 50µM DAG for 24 hours produced a significant increase in active PKC δ 
(14.2%), but no correspondingly significant decrease in inactive PKC δ (0.6%). 
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7.2.3 PKC ι 
7.2.3.1 Treatment of MDA-MB-231 Cells With 25µM CLA. 
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Figure 7.5: Effect of CLA’s on PKC ι. MDA-MB-231 cells treated with 25µM CLA 
isoforms or 25µM DAG. ß-actin was used to verify loading in cytosolic protein samples, 
Claudin-3 was used to verify loading in membrane bound protein samples. Data are from 
three independent experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 
 
Statistical significance was observed in cells treated with the t10:c12 isomer alone for 
both the active and the inactive PKC ι, a decrease of 11.0% is observed in the active form, 
and a decrease of 29.2% for the inactive form (Figure 7.5). The LA treatment caused a 
significant increase (6.6%) in the amount of membrane bound PKC ι, with a 
corresponding, but non significant decrease of 2.9% in the cytosolic protein. Small, non 
significant changes were observed in the membrane bound PKC ι of cells treated with the 
50:50 isomer mix, and the c9:t11 isomer. A non significant decrease of 2.7% in active 
PKC ι was observed in cells treated with the isomer mix and a decrease of 4.27% in cells 
treated with the c9:t11. Cytosolic PKC ι was decreased by 11.6% after treatment with the 
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isomer mix, and by 33.5% after treatment with the c9:t11 isomer alone, however only the 
latter is statistically significant. 
 
Treatment with 25µM DAG for 24 hours produced a small decrease of 1.4% in active 
PKC ι, and a similar decrease of 3.6% in inactive PKC ι. Neither of these was statistically 
significant.  
 
7.2.3.2 Treatment of MDA-MB-231 Cells With 50µM CLA. 
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Figure 7.6: Effect of CLA’s on PKC ι. MDA-MB-231 cells treated with 50µM CLA 
isoforms. ß-actin was used to verify loading in cytosolic protein samples. Data from three 
independent experiments.  
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. P<0.05 
 
Membrane abundance of active PKC ι was significantly decreased in cells treated with 
50µM of the c9:t11 or t10:c12 isomers respectively (16.4% and 28.0%, Fig 7.6). With the 
c9:t11 treatment the inactive cytosolic PKC ι was decreased by 17.0 % and by 16.2% in 
cells treated with the t10:c12 isomer. The cells treated with LA at the 50µM concentration 
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showed a non significant decrease of 6.7% in the amount of active PKC ι, and a 
corresponding increase of 13.2% in the cytosolic PKC ι. Cells treated with the 50:50 mix 
of isomers showed a 1.7% decrease in active PKC ι and an 11.1% decrease in inactive 
PKC ι. The membrane abundance of active PKC ι exhibits a decrease of 2.4% in cells 
treated with 50µM DAG, the comparative decrease in cytosolic PKC ι was 0.5%, neither 
of these results show statistical significance.  
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7.3 Discussion  
Effects of Treatment With CLA in Oestrogen Receptor Negative Cells on Abundance of 
Active and Inactive PKC.  
 
The androgen independent prostate cancer cell line, known as PC-3 may be considered to 
be somewhat analogous with MDA-MB-231 breast cancer cell line. Both cell lines fail to 
express the hormone receptors which are the targets for several different 
chemotherapeutic drugs. CLA is known to decrease levels of the anti-apoptotic protein 
Bcl-2 in PC-3 cells, although at 25 and 50µM concentrations this is not significant (Ochoa 
et al. 2004). It has been suggested that CLA acts through the ER receptors in breast cancer 
cells (Wang et al. 2008), however the results in this study show a greater increase in cell 
death after CLA treatment in the MDA-MB-231 cell line. 
 
Since PKC δ and PKC α are known modulators of Bax, and Bad it is tempting to assume 
that an increase in PKC δ, and a decrease in PKC α will lead to apoptosis. In the MDA-
MB-231 cell line this does not appear to happen. At 25µM concentrations of CLA the 
levels of active PKC α and PKC δ both decrease significantly (P<0.05), while at 50µM 
concentrations they both increase. When the large increase in apoptosis observed in 
chapter 4 is taken into account this may suggest that the idea of the traditional Bcl-2 
pathway being modulated by the PKC isoforms does not tell the whole story. Similarly, 
the decrease of active PKC ι at 25µM of CLA, and its increase at 50µM does not fit the 
traditional role of apoptotic inhibitor assigned to this protein. The reasons for this result 
are currently unclear, and require further investigation. 
 
It does not appear, given the activation pattern of PKC after treatment with 50µM CLA in 
the current research, that the PKC/Bcl-2 pathway is the mechanism by which CLA causes 
apoptosis in MDA-MB-231 cells. If that was the case then the increases in PKC α after 
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treatment with the cis-9:trans-11, and trans-10:cis-12 isomers alone would be expected to 
decrease apoptosis. The results from chapter four clearly show that this is not occurring. It 
appears likely that the PKC isoforms are acting through a different pathway, possibly by 
the translocation of active PKC δ directly to the mitochondrial membrane. Given the 
decrease in PKC α at the 25µM treatments it is possible that apoptosis is being controlled 
through two different pathways, depending on the concentration of CLA used to treat the 
cells. The Bcl-2 pathway may be a candidate at lower concentrations, and membrane 
incorporation of CLA may be assisting apoptosis at higher concentrations. Previous 
research into the action of CLA on MDA-MB-231, and androgen insensitive prostate 
cancer cell lines, is somewhat limited. It does, however, suggest that CLA causes 
apoptosis, especially at high concentrations of CLA. Migiletta et al. suggested in 2006 
that CLA caused apoptosis in MDA-MB-231 cells by inducing cytosolic release of 
cytochrome c from the mitochondria. This was in direct contrast to previous research 
which had suggested that CLA was acting to cause apoptosis via oestrogen response 
elements (Tanmahasamut et al. 2004). 
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Chapter 8 
The Effect of CLA (50µM) on the RNA Expression in MCF-7 Cells 
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8. The Effect of CLA (50µM) on the RNA Expression in MCF-7 Cells. 
8.1 Introduction 
The Reverse Transcription Polymerase Chain Reaction (RT-PCR) is a semi-quantative 
technique which allows amplification of a defined piece of RNA. RT-PCR can be 
performed as either a one step, or two step process.  Generally RT-PCR is performed as 
follows: 
1. RNA is extracted from treated cells using a Trizol based process (see Chapter2, 
page 57 for more detail).  
2. RNA is reverse transcribed into complimentary DNA (cDNA). 
3. Complimentary DNA is amplified using primers specific for the gene of interest 
(see also Fig 8.1)  
 
Fig 8.1 RT-PCR 
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8.1.1 Primer design 
Primers are required for the amplification of the correct gene sequence during the PCR 
step. Typically primers are “paired”, with one reading from the 5’ end of the cDNA to the 
3’ end, and the other starting at the 3’ end, and reading to the 5’end. Paired primers ensure 
that the cDNA produced is double stranded, allowing binding by DNA polymerases 
(usually Taq from the Thermus aquaticus bacterium). 
 
Primer design must follow several criteria to maximize the chance of amplifying the 
correct genomic sequence. Primers must be specific to the sequence being amplified. To 
achieve reasonable fidelity in this most primers are designed to be between 18 and 25 
bases long. This length is optimal, as it is short enough to allow binding at the annealing 
temperature, yet long enough to ensure adequate specificity. Primers which are 
amplifying a piece of cDNA of transcriptional origin must furthermore contain no 
untranscribed sequences. The area of cDNA being amplified (the amplicon) may be of 
variable length, but 100-500 base pairs is generally considered to be optimum. Because a 
single strand of cDNA is a naturally unstable construct in that it preferentially binds to 
another strand, it is vitally important to avoid the presence of secondary structures within 
the amplicon itself. If the cDNA is folded back on itself it is much more difficult for the 
primers to bind faithfully. Equally the primers themselves must be designed to avoid 
either the formation of primer dimers, or secondary structures within the primer, as again 
this makes binding to the cDNA almost impossible. Long repeated sequences, and single 
base repeats in the primer region should also be avoided as they have a higher chance of 
mispriming. The maximum number of repeats is thought be four (e.g ATATATAT). 
Finally, the temperatures at which the primers anneal (Ta) and melt (Tm, defined as the 
temperature where the number of paired nucleotides are equal to the number of unpaired 
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nucleotides, (Wetmur, 1991) is very important, for maximal PCR product yield; the two 
primers should have a very closely matched Ta and Tm. 
 
There are three methods used for calculating Tm, known as the Arbitrary Method, the 
Nearest Neighbour Method, and the Long Probe method. 
 
1. The Arbitrary Method was first mentioned by Wallace et al. in 1979, and is worked out 
as: 
Tm=2(A + T) + 4(G + C) 
Where A is the number of Adenine bases in the Primer, G the number of Guanine bases, T 
the number of Thymine bases, and C the number of Cytosine bases. 
 
2. The Nearest Neighbour method was first described by Borer et al. in 1974, and is 
generally considered to be the most accurate calculation of Tm: 
Tm=(-1000 x ∆H) / (-10.8 - ∆S + R x ln(2.5^c/4)) - 273.15 - 16.6(log10 M) 
In this case ∆H is the enthalpy of base stacking interactions (adjusted for helix initiation 
factors), ∆S is the entropy of base stacking (adjusted for helix initiation factors, and for 
the contributions of salts), R is the gas constant (1.987), c is the molar concentration of 
primer (250 pM), and M is the molar concentration of Na+ (50 mM). 
 
3. The Long Probe method first appeared in a paper by Meinkoth and Wahl in 1984 and 
may be described as: 
Tm=81.5 + 16.6(log10 M) + 0.41(% GC) - 0.61(% form) - 500 / Length in bp 
M is again the molar concentration of Na+ (set at 0.75 M) and % form is the percentage of 
formamide (set to 50%). 
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8.1.2 Experimental Aims 
The current research shows significant changes in the activation of the three PKC 
isoforms in cells treated with CLA. RNA extraction techniques and RT-PCR, using 
specifically designed primers will help to indicate whether these changes are the result of 
increased transcription of the PKC genes.  
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8.2 RT-PCR Results 
8.2.1 Developing a Time Course 
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Fig 8.2 Time course study. PKC α RNA expression in MCF-7 cells treated with 50µM 
CLA isoforms or equivalent volume of ethanol, for 3, 6, and 12 hours. ß-actin was used as 
a housekeeping gene.  
Key: Control – 100% ethanol (equivalent volume); 10:12 - 50µM t10:c12 isomer alone. 
P<0.05 (*) 
 
Expression of PKC α RNA (Fig 8.2) showed a general decrease at all time points studied, 
with only the 12 h treatment exhibiting a significant decrease (16.6%). 
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8.2.2 Expression of PKC α after 12 hours treatment with 50µM CLA 
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Fig 8.3 PKC α RNA expression. PKC α RNA expression in MCF-7 cells treated with 
50µM CLA isoforms or equivalent volume of ethanol. ß-actin was used as a housekeeping 
gene.  
Key: Control – 100% ethanol (equivalent volume); LA – 50µM Linoleic Acid; Mix – 
50µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 50µM c9:t11 isomer alone; 
10:12 - 50µM t10:c12 isomer alone. P<0.05 
 
Transcription of PKC α RNA can be seen to increase (6.6%) after 12 hours treatment with 
50µM LA (Fig 8.3). With the 50:50 isomer mix PKC α RNA transcription also increased 
by 23.0%. However treatment with the c9:t11 and t10:c12 isomers alone showed a 
decrease in PKC α transcription by 12.1% and 23.3% respectively. Only the result for the 
50:50 mix and the t10:c12 treatment alone showed any statistical significance. 
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8.2.3 Expression of PKC δ RNA after 12 hours treatment with 50µM CLA 
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Fig 8.4 PKC δ RNA expression. PKC δ RNA expression in MCF-7 cells treated with 
50µM CLA isoforms or equivalent volume of ethanol. ß-actin was used as a housekeeping 
gene. 
Key: Control – 100% ethanol (equivalent volume); LA – 50µM Linoleic Acid; Mix – 
50µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 50µM c9:t11 isomer alone; 
10:12 - 50µM t10:c12 isomer alone. P<0.05 
 
Transcription of PKC δ RNA showed a 2.9% decrease with 12 hours treatment of 50µM 
LA (Fig 8.4). With the 50:50 isomer mix and the c9:t11 isomer alone PKC δ RNA 
transcription was increased by 7.9% and 7.8% respectively. Treatment with the t10:c12 
isomer alone caused a significant (15.3%) increase in PKC δ transcription.  
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8.2.4 Expression of PKC ι after 12 hours treatment with 50µM CLA 
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Fig 8.5 PKC ι RNA expression . PKC ι RNA expression in MCF-7 cells treated with 
50µM CLA isoforms or equivalent volume of ethanol. ß-actin was used as a housekeeping 
gene.  
Key: Control – 100% ethanol (equivalent volume); LA – 50µM Linoleic Acid; Mix – 
50µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 50µM c9:t11 isomer alone; 
10:12 - 50µM t10:c12 isomer alone. P<0.05 
 
Transcription of PKC ι RNA showed a decrease by 7.5% in cells treated with 50µM LA 
(Fig 8.5). With the 50:50 isomer mix PKC ι RNA transcription increased by 0.2%. 
Treatment with the c9:t11 isomer and t10:c12 isomers each caused a decrease in PKC ι 
transcription by 7.2% and 16.6% respectively. None of these results showed any statistical 
significance. 
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8.3 Discussion   
8.3.1 Effects of CLA on the expression PKC RNA in MCF-7 Cells 
The above results clearly show a correlation between treatment with CLA and the 
regulation of PKC α, δ, and ι transcription.  
 
8.3.1.1 Time Course Experiment 
The time course experiments were performed at 3, 6, and 12 hours. It was decided to look 
at MCF-7 cells, partly due to time, and cost constraints, and partly because MCF-7 is the 
model for the far more common type of breast cancer, so the results from these 
experiments would have a much greater practical impact. 
 
Based on the results from the protein analysis as described in chapters 6 and 7, and also 
the work of Song et al. it is clear that the t10:c12 isomer alone had the greatest single 
impact on all three PKC isoforms. In general, treatments with 50µM of CLA had a greater 
impact than treatments with 25µM. From this it was decided to use the t10:c12 at 50µM 
for the whole RT-PCR time course. PKC α was the obvious choice of isoform for the time 
course because the primers had already been optimised for use with RNA extracted from 
MCF-7 cells.  
 
The time course experiment confirmed that significant effect occurred only after 12 hours. 
This was a somewhat longer period than was first expected, however some effect was 
apparent even after three hours. The decrease in the amount of PKC α RNA appears to 
decrease very steadily, then tail off over the time course. The decrease between 0 and 3 
hours is around 5%, as is the decrease between 3 and 6 hours. Between 6 and 12 hours 
this steady decrease can be seen to tail off, as the decrease is around 6%, correlating to a 
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decrease of around 1% an hour, compared with approximately 1.7% per hour seen 
previously. A fourth time point at 9 hours would show more precisely how this decline 
occurs. 
 
8.3.1.2 Effect of CLA on the expression of PKC α mRNA 
The expression pattern of the PKC α RNA almost matches the expression pattern of the 
PKC α protein in MCF-7 Cells treated with 50µM CLA. Actual and precise correlation is 
difficult to assess as the method of measuring both involves measuring intensity of signal 
as a percentage of the control, rather than an actual amount of protein. It is further 
complicated by the fact that no total protein data for PKC α has been done. As it stands it 
appears that levels of PKC α protein in cells treated with 50µM of LA, c9:t11 alone, and 
t10:c12 alone all decrease slightly, while PKC α protein in cells treated with 50µM of the 
50:50 isomer mix increase slightly. This is a very inaccurate measure as it assumes that 
active and inactive isomers of PKC α are found in the same levels in the cytosol and the 
membrane. The increase in PKC α RNA, observed after treatment with the isomer mix, 
and the decreases seen after treatment with the c9:t11, and t10:c12 isomers alone mirrors 
this, although there are several anomalies. While both the active and inactive PKC α 
protein appears to decrease in cells treated with the c9:t11 isomer alone, inactive PKC α 
increases by a significant amount in cells treated with the t10:c12 isomer alone. This may 
be partly due to the equally significant decrease in active PKC α leaving a greater amount 
of inactive PKC α in the cytosol. The apparent differences in activation as well as PKC α 
protein production suggest that the CLA isoforms may be exerting a dual effect, both on 
the cell membranes, making them more, or less likely to allow PKC α activation, and on 
the transcription of RNA in the cell. 
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8.3.1.3 Effect of CLA on the expression of PKC δ mRNA  
The expression pattern of both the active, and the inactive PKC δ protein shows a very 
high degree of correlation with the expression of PKC δ RNA in MCF-7 cells treated with 
50µM of CLA. The only anomaly is in the cells treated with LA, where the active PKC δ 
protein increases, while the inactive PKC δ protein decreases slightly. However, the RNA 
shows a slight decrease in transcription, although again this may be explained by the 
difficulty in assessing actual relative amounts of protein. It is also worth noting that all the 
protein assessments were done after 24 hours treatment with CLA, it may be that the 
results after 12 hours would reflect the RNA expression pattern more closely. 
 
In cells treated with 50µM the 50:50 mix, the c9:t11 alone, and the t10:c12 alone there are 
increases in both the active and inactive PKC δ, this is similar to the pattern which is 
observed in the RNA expression after treatment with the same isoforms. The dual increase 
suggests that, in the case of PKC δ, the increased level of PKC δ RNA transcription after 
treatment with CLA causes greater translation of PKC δ protein. There may of course be 
differences if the experiment was repeated using total protein extracts, but these may be 
caused by the differences in isoform activation, as PKC δ localisation is affected by 
caspase activity, or by an, as yet un-looked for effect of CLA on the cell membrane. 
 
8.3.1.4 Effect of CLA on the expression of PKC ι mRNA 
There appears to be no correlation between the expression of PKC ι RNA and PKC ι 
protein in MCF-7 cells treated with 50µM of CLA. RNA expression shows no significant 
decrease after treatment, but does show a decrease, while the protein activation increases 
dramatically with every treatment. Protein expression appears to be increased in all the 
samples, despite the difficulty in assessing actual amounts of protein. To assess actual 
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total PKC ι protein levels after treatment would require further work involving total 
protein extraction. It may be that if the cells from which the RNA was extracted were 
treated for 24 hours in the way that the cells from which the protein was extracted were a 
different result, possibly involving an increase in mRNA expression, would be observed. 
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9. Summary, Conclusions, and Future Work 
 
9.1 Summary 
 
The current research shows increases and decreases in the abundance of active PKC 
isoforms after treatment with different concentrations of CLA. The t10:c12 isomer of 
CLA appears to show the greatest, and most consistent, effect in breast cell lines (MCF-7 
and MDA-MB-231) studied, both at the level of an mRNA transcription, and protein 
activation (as measured by translocation of protein to the membrane throughout). 
 
9.1.1 Summary of the effects of the t10:c12 Isomer on MCF-7 and MDA-MB-231 Cells 
 
In MCF-7 cells the t10:c12 isomer (at 25 and 50µM concentrations) causes a decrease in 
PKC α protein activation, and a significant reduction in cell viability. Furthermore at 
50µM, a significant decrease in PKC α mRNA transcription is also observed. In the 
MDA-MB-231 cells PKC α protein activation is significantly decreased at 25µM 
concentrations, while the reverse is observed at 50µM. It must be noted that cell viability 
is decreased at both concentrations in MDA-MB-231 cells.  
 
PKC δ protein activation is slightly less consistent, with reductions occurring at 25µM 
concentrations in both cell lines while increases occur at 50µM. Transcription of PKC δ 
mRNA in MCF-7 cells is significantly increased after treatment with 50µM of the t10:c12 
isomer, suggesting that the decrease seen at 25µM may be due to other factors.  
Here we show for the first time that PKC ι is present in detectable quantities in both the 
MCF-7 and MDA-MB-231 breast cancer cell lines (Nutrition Society Abstract, 2004). 
However, previous work had only detected the presence of PKC ι protein in serum starved 
MCF-7 cells (Muscella et al. 2005). Recent work by Kojima et al. (2008) reported that 
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PKC ι is over expressed in 88 out of the 100 cases of mammary tumours studied. PKC ι 
mRNA transcription decreases after treatment with the t10:c12 isomer (50µM). However, 
in the same cell line (MCF-7) both 25 and 50µM cause an increase in protein activation of 
PKC ι, while in MDA-MB-231 cells a decrease in protein activation is seen. 
 
9.1.2 Summary of the effects of the c9:t11 Isomer on MCF-7 and MDA-MB-231 Cells 
In MCF-7 cells the c9:t11 isomer causes the greatest reduction in cell viability, although 
this is not significant when compared with the decrease caused by the mix and t10:c12 
isomer. In MDA-MB-231 cells however the c9:t11 isomer causes the smallest decrease in 
cell viability. Similarly this is not significant when compared with the mix and t10:c12. 
 
PKC α protein activation is decreased after treatment (25 and 50µM concentrations) with 
the c9:t11 isomer in MCF-7 cells. A similar reduction is observed with 25µM of c9:t11 in 
the MDA-MB-231 cells. However, at 50µM in the MDA-MB-231 cells the activation of 
PKC α protein increases in a similar manner to t10:c12 isomer. Expression of PKC α 
mRNA in MCF-7 cells treated with 50µM of c9:t11 is decreased, although not 
significantly. 
 
PKC δ protein activation exhibits a similar pattern in cells treated with the c9:t11 isomer 
to the one seen in cells treated with the t10:c12 isomer. Only one point of difference 
actually exists, and that is a non-significant increase in protein activation in MCF-7 cells 
treated with 25µM. Generally cells treated with the t10:c12 isomer exhibit a greater 
increase or decrease in protein activation than the c9:t11 isomer. The exception to this, are 
MCF-7 cells treated with 50µM of c9:t11 which exhibit greater activation of PKC δ 
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In MCF-7 cells treated with the c9:t11 isomer, PKC ι protein activation increases, 
significantly at 25µM, and not significantly at 50µM. This difference in significance may 
be due to the statistical test used (Mann-Whitney paired t-test). Expression of PKC ι 
mRNA in the same cell line (MCF-7) also decreases without significance. MDA-MB-231 
cells treated with either 25 or 50µM of the c9:t11 isomer exhibit a decrease in the active 
PKC ι protein, although, as with PKC δ, not to the same extent as in cells treated with the 
t10:c12 isomer. 
 
9.1.3 Summary of the effects of the Isomer Mix on MCF-7 and MDA-MB-231 Cells 
At both concentrations (25 and 50µM)  and in both cell lines the isomer mix generally 
provokes either the most minimal effect, or a totally opposing effect, on the mRNA 
expression and protein activation of all three isoforms of PKC. In MCF-7 cells viability is 
generally lower when treated with the mix, than with the t10:c12 isomer. In MDA-MB-
231 cells viability is lower with the mix than with the c9:t11 isomer.  
 
Expression of PKC α mRNA is significantly increased after treatment with the isomer mix 
when compared with individual c9:t11, and t10:c12 isomers. After treatment with 25µM 
of the isomer mix a small increase in PKC α protein activation is seen in MCF-7 cells. 
This is compared with the decrease observed after treatment with the same concentration 
of individual isomers. In MCF-7 cells (50µM isomer mix), PKC α protein activation is 
decreased. In MDA-MB-231 cells a decrease in the activation of PKC α protein is 
observed with 25µM of the isomer mix, while an increase is recorded with the 50µM 
concentration, neither of these are significant. 
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PKC δ expression and activation are both increased in MCF-7 cells after treatment with 
50µM of the isomer mix. Treatment with 25µM however produces a non-significant 
decrease, similar to that produced by treatment with the t10:c12 isomer alone. Similar 
observations are observed in MDA-MB-231 cells. 
 
Increases in PKC ι protein activation are observed in MCF-7 cells after both treatments 
(25 and 50µM). An insignificant increase in PKC ι mRNA expression is also seen in this 
cell line after treatment with 50µM of the isomer mix. In MDA-MB-231 cells only a 
small decrease of PKC ι activation after both treatments is observed. 
 
9.1.4 Summary of the effects of Linoleic acid on MCF-7 and MDA-MB-231 Cells 
Treatment with LA caused no significant change in cell viability compared with the 
control at either concentration (25 and 50µM).  
 
There was a small increase in PKC α protein activation in MCF-7 cells treated with 25µM 
of LA, and in cells treated with 50µM. PKC α mRNA expression exhibited a small 
increase in the same cell line. A similar increase in PKC α protein activation was 
exhibited by MDA-MB-231 cells treated with 25µM; however, a decrease was seen in 
those cells treated with 50µM. 
 
PKC δ mRNA expression was non-significantly decreased in MCF-7 cells treated with 
50µM of LA, however, PKC δ protein activation was increased in the same cells. In cells 
treated with the 25µM concentration activation was almost unchanged compared to the 
control. Activation of PKC δ protein in MDA-MB-231 cells followed a similar pattern to 
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that observed after treatment with the isomer mix, although activation was slightly greater 
in cells treated with 50µM of LA. 
 
PKC ι protein activation was significantly increased in MCF-7 cells treated with a 
concentration of 25µM of LA. Similarly cells treated with 50µM of LA also showed 
increased PKC ι protein activation, however PKC ι mRNA expression was slightly 
decreased. In MDA-MB-231 cells the activation also increased (25µM concentration), 
again significantly, and in contrast to the decrease in activation caused by every other 
treatment at the same concentration.  PKC ι protein activation in the same cell line treated 
with 50µM of LA exhibited a non-significant decrease. 
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9.2 Conclusions 
9.2.1 Effects of Treatment with CLA Isoforms on MCF-7, and MDA-MB-231 Cells. 
Table 1.1 (Chapter 1, page 24) summarised the general effects of the various PKC 
isoforms. It would therefore be expected, given that treatment with CLA caused 
significant apoptosis (as demonstrated in chapter 4), that both cell lines would exhibit an 
increase in activation of the pro-apoptotic isoforms, and a decrease in activation of the 
anti-apoptotic isoforms. This does not appear to be the case for all treatments. PKC α, a 
known promoter of cell survival, exhibits significant increase in its activation in MDA-
MB-231 cells treated with both the c9:t11, and t10:c12 isomers at 50µM. These two CLA 
isomers definitely cause a reduction in PKC α protein activation in MCF-7 cells, and at 
lower concentration (25µM) the same effect is observed in MDA-MB-231 cells. This 
anomaly in the cells which have exhibited the greatest loss in viability (MDA-MB-231, 
50µM) strongly suggests that CLA is acting through multiple pathways. Equally the 
dramatic increase in activation of PKC ι protein in treated MCF-7 cells is in direct 
contrast to the considerable recent research which implicates it as a potent cell survival 
factor and oncogene (Eder et al. 2005, Fields et al. 2007). The activation pattern of PKC ι 
protein in MDA-MB-231 cells shows a decrease which would be expected in cells 
undergoing apoptosis. This is borne out by the fact that MCF-7 cells treated with CLA are 
apparently more viable. Possibly PKC ι is activated in these cells in response to cellular 
stress.  
 
PKC δ is considered to be highly pro-apoptotic, and the significant increase in its 
activation in MCF-7 cells treated with 50µM of CLA is entirely consistent with this. 
However at 25µM of CLA the effect observed was not consistent. In MDA-MB-231 all 
 154 
CLAs (25µM) cause a decrease in the activation of PKC δ protein. At 50µM of CLA PKC 
δ protein activation is increased as found in the MCF-7 cells. 
 
Because the results collected use transcriptional and activation data, it is difficult to 
conclude whether CLA is acting entirely at a genetic level. This, and previous research, 
would appear to suggest that both genetic and physiological factors are playing a part in 
the chemoprotective, and chemotheraputic effects of CLA in breast cancer. CLA, as a 
fatty acid may well be affecting cellular signalling, by incorporation into cellular 
membranes. 
 
9.2.2 CLA as a Cancer Treatment. 
Currently the in vivo and in vitro results available from studies into the effect of CLAs on 
breast cancer cells do not correlate well. The strongly chemotherapeutic, and 
chemoprotective effect observed in vitro is not as pronounced in in vivo studies. Some in 
vivo studies either do not show any effect at all, or even show a totally opposing effect. 
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9.3 Future Work 
9.3.1 CLA Incorporation into Cellular Membranes 
Given the somewhat unexpected results of the current research it now appears that CLA is 
involved in more than just altering genetic expression. It is important to look, not just at 
the up and down regulation of the active form of these isomers, but also at their enzymic 
activity. This has a profound effect on how the isoforms exert their effects within the cell. 
The incorporation of CLA into cellular membranes, and its effects on protein activation 
when there, is an area of research which may prove fruitful in the future. Incorporation of 
radio labelled CLA isomers into the cell membranes, coupled with tagging of the various 
PKC isoforms to measure activation would help in bringing this about. An understanding 
of how CLA affects the physiology of the cell will assist our understanding of how it 
exerts its multifarious effects. 
 
9.3.2 CLA as a Chemoprotective Agent 
The use of CLA as a chemoprotective agent has not been explored in the current research. 
Based on its effect on the PKC α isoform, which is known to affect the resistance of 
breast cancer cells to chemotherapeutic drugs, it may be that the decrease in the active 
form of this isomer after treatment with the c9:t11 and t10:c12 isomers alone plays a role 
in chemoprotection. This decrease may begin in normal cells, and prevent levels of PKC α 
reaching the peaks required to cause significant apoptotic resistance. The significant 
increases in the abundance of active PKC δ caused by treatment with 50µM of the c9:t11 
and t10:c12 isomers alone in both MCF-7 and MDA-MB-231 cells may also be a 
significant factor in the chemoprotective effect of CLA. PKC δ is known to promote 
apoptosis, and significantly increased levels may persist even after treatment has been 
stopped. 
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Data relating to the decline of active PKC isoforms in cells after prolonged treatment with 
CLA, as well as the IC50 value of CLA (measured by competition binding assays) in 
animal models has not, as yet, been published. Also required are tests on serum 
concentrations of CLA to measure how fast it is cleared from the body, both in animals 
and humans. The results from these experiments would provide a clearer picture of how 
the CLA exerts its effects on cells, at a physiological level. They would also provide an 
idea of what CLA intake in grams per day is required to exert an effect on cells in the 
body.  
 
9.3.3 The Chemoprotective Effect of CLA in Human Studies   
The evidence for a chemoprotective effect by CLA is primarily based on studies done on 
animal models and with cancer cells in vitro, potentially warranting more studies on CLA 
intake, and chemo-protectiveness in humans. The limited studies of CLA performed in 
human populations so far, have been somewhat inconclusive. The section below details 
the methods and findings of the largest of these. 
 
9.3.3.1 The Netherlands Cohort Study 
The Netherlands Cohort Study on Diet and Cancer (Voorrips et al. 2002), looked at the 
intake of CLA, as well as other fatty acids in 62,573 postmenopausal women (between 
55-69 years old). The study took the form of self completed questionnaires, looking at 
personal and family cancer incidence, lifestyle and dietary habits. The food frequency 
section of the study was semi quantative, comprising 150 items, and concentrating on the 
habitual consumption of food and beverages. Observer bias was minimised by use of a 
blinding system to mask the sub-cohort status of the subjects. Specific fatty acid intake 
 157 
was calculated using a database derived from the TRANSFAIR study of 1999 (Hulshof et 
al. 1999), involving the sampling and analysis of foods from 14 European countries (a 
maximum of 100 foods per country). The mean CLA consumption by volunteers was 
0.2g/d (± 0.1), a sub cohort, made up of 941 women who went on to develop breast 
cancer, and 1598 control women (without breast cancer) was left for analysis after 6.3 
years. A multivariate analysis showed no statistical significance between the incidence of 
breast cancer, and fat, or energy intake, including separate analyses for intake of vegetable 
fats, animal fats, total fatty acids, and total polyunsaturated fatty acids. There was 
however a higher incidence of breast cancer among volunteers who consumed the higher 
amounts of trans unsaturated fatty acids, and a weakly positive trend with regards to 
breast cancer incidence was observed in those who consumed a higher amount of CLA, 
although this did not appear to be related to consumption of milk, milk products, fresh, or 
processed meat. 
 
9.3.3.2 The Finnish Study 
Between 1992 and 1995 levels of dietary and serum CLA were looked at in 195 Finnish 
patients with either pre, or postmenopausal breast cancer, and compared to 208 control 
subjects without cancer. The results by Aro et al. in 2000 showed that women suffering 
from postmenopausal breast cancer had significantly lower levels of both serum, and 
dietary CLA, as well as lower levels of myristic, and trans-vaccenic acid. As in the 
Netherlands study, validated food frequency questionnaires were used to determine 
dietary levels of the various fatty acids. 
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9.3.3.3 The WEB study 
The WEB study of 2004 (McCann et.al) looked at intake of dietary CLA by 1122 women 
with breast cancer, and 2036 healthy control subjects in Western New York (USA). As in 
previous studies the majority of subjects were of Caucasian origin, although it was the 
first of its kind to take place in the USA. In this study intake of both total CLA, and of the 
c9:t11 isomer alone was measured using a food frequency questionnaire, which, as in the 
other studies was self administered.  The WEB study observed no association between 
CLA intake, and breast cancer risk, either pre, or post menopausal. There was however, 
an indication that increased consumption of the c9:t11 isomer alone may be linked to a 
reduced risk of premenopausal subjects presenting with ER- tumours. This was apparently 
not statistically significant. This final result may be linked to the results of chapter 4 in the 
present study, which showed a definite decrease in cell viability for the MDA-MB-231 
cells which had been treated with 50µM of CLA for 24 hours. 
 
9.3.3.4 Limitations of These Studies 
It is worth noting that only one of these studies actually looked at serum concentrations of 
CLA, which are a more accurate assessment of CLA uptake by the body (although not as 
accurate as assessments of levels of CLA in red blood cell membranes), and this was the 
study which showed a correlation between breast cancer risk and CLA intake. 
Questionnaires are a much cruder method of measuring intake of any food type, with so 
much food being bought pre-packaged, and pre-prepared it is more difficult to be 
accurate. Because different companies will rely on slightly different recipes for their 
products it is difficult to get a true representation of the intake of a particular nutrient, also 
people will have differing ideas as to what constitutes a “portion”. Food questionnaires 
also rely on the respondent remembering to note down the exact contents of every meal, 
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and do not usually take in to account any change in dietary habits bought about by a 
diagnosis of cancer.  
 
What is really required in this field is a study focussing on CLA supplementation and 
serum concentrations, and how it affects breast cancer incidence, survival and tumour 
size.  
 
9.3.3.5 Future Studies into CLA Intake and Breast Cancer. 
Because CLA is already a recognised supplement, and sold as such, both in the US and 
the UK, it would be possible to measure its intake with a much higher degree of success 
in human trials. One possible downside to this is the fact that many of the over the counter 
preparations of CLA are derived from Safflower Oil, rather than animal fats so before any 
clinical trials could go ahead an initial study into the efficacy of these preparations would 
need to be carried out. Once the fitness of these supplements was proved a possible 
human based study would involve patients who had undergone surgery to remove 
tumours. Patients could be asked to take either the supplement, or a placebo (possibly 
Olive Oil) after surgery, and their likelihood of recurrence measured. It would be hoped 
that supplementation with the CLA would reduce the recurrence of breast tumours, and 
reduce the mean size of tumours in women who did suffer a recurrence. Other 
possibilities would involve asking patients to take CLA or a placebo as an adjunct to 
Tamoxifen therapy, or between diagnosis and surgery to look at their effects on tumour 
size. Such studies would be much more controlled than previous ones, and could 
potentially give a more accurate picture of the benefits of CLA to human health.  
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 V 
ANOVA Analysis Performed on Cell Viability Data (Chapter 4). 
 
Multiple Comparisons 
Dependent Variable: % Viable cells  
Tukey HSD  
(I) 
Treatment 
(J) 
Treatment Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval 
        Lower Bound Upper Bound 
Con LA -1.27333% 1.49584% .908 -6.1963% 3.6496% 
  Mix 23.58333%(*) 1.49584% .000 18.6604% 28.5063% 
  9:11 24.51667%(*) 1.49584% .000 19.5937% 29.4396% 
  10:12 17.13667%(*) 1.49584% .000 12.2137% 22.0596% 
LA Con 1.27333% 1.49584% .908 -3.6496% 6.1963% 
  Mix 24.85667%(*) 1.49584% .000 19.9337% 29.7796% 
  9:11 25.79000%(*) 1.49584% .000 20.8671% 30.7129% 
  10:12 18.41000%(*) 1.49584% .000 13.4871% 23.3329% 
Mix Con -23.58333%(*) 1.49584% .000 -28.5063% -18.6604% 
  LA -24.85667%(*) 1.49584% .000 -29.7796% -19.9337% 
  9:11 .93333% 1.49584% .968 -3.9896% 5.8563% 
  10:12 -6.44667%(*) 1.49584% .010 -11.3696% -1.5237% 
9:11 Con -24.51667%(*) 1.49584% .000 -29.4396% -19.5937% 
  LA -25.79000%(*) 1.49584% .000 -30.7129% -20.8671% 
  Mix -.93333% 1.49584% .968 -5.8563% 3.9896% 
  10:12 -7.38000%(*) 1.49584% .004 -12.3029% -2.4571% 
10:12 Con -17.13667%(*) 1.49584% .000 -22.0596% -12.2137% 
  LA -18.41000%(*) 1.49584% .000 -23.3329% -13.4871% 
  Mix 6.44667%(*) 1.49584% .010 1.5237% 11.3696% 
  9:11 7.38000%(*) 1.49584% .004 2.4571% 12.3029% 
*  The mean difference is significant at the .05 level. 
Table 4.1: ANOVA test of values from MCF-7 Cells treated with 25µM CLA. 
Percentage of viable cells after 24 hours treatment with 25µM CLA. Average of three 
experiments, cells incubated with Tryphan Blue. 
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. 
 
 VI
Multiple Comparisons 
Dependent Variable: % viable cells  
Tukey HSD  
(I) 
Treatment 
(J) 
Treatment 
Mean Difference 
(I-J) Std. Error Sig. 95% Confidence Interval 
        Lower Bound Upper Bound 
Con LA 2.3733333% 1.8168985% .694 -3.606229% 8.352895% 
  Mix 32.3600000%(*) 1.8168985% .000 26.380438% 38.339562% 
  9:11 34.4000000%(*) 1.8168985% .000 28.420438% 40.379562% 
  10:12 32.0733333%(*) 1.8168985% .000 26.093771% 38.052895% 
LA Con -2.3733333% 1.8168985% .694 -8.352895% 3.606229% 
  Mix 29.9866667%(*) 1.8168985% .000 24.007105% 35.966229% 
  9:11 32.0266667%(*) 1.8168985% .000 26.047105% 38.006229% 
  10:12 29.7000000%(*) 1.8168985% .000 23.720438% 35.679562% 
Mix Con -32.3600000%(*) 1.8168985% .000 -38.339562% -26.380438% 
  LA -29.9866667%(*) 1.8168985% .000 -35.966229% -24.007105% 
  9:11 2.0400000% 1.8168985% .792 -3.939562% 8.019562% 
  10:12 -.2866667% 1.8168985% 1.000 -6.266229% 5.692895% 
9:11 Con -34.4000000%(*) 1.8168985% .000 -40.379562% -28.420438% 
  LA -32.0266667%(*) 1.8168985% .000 -38.006229% -26.047105% 
  Mix -2.0400000% 1.8168985% .792 -8.019562% 3.939562% 
  10:12 -2.3266667% 1.8168985% .708 -8.306229% 3.652895% 
10:12 Con -32.0733333%(*) 1.8168985% .000 -38.052895% -26.093771% 
  LA -29.7000000%(*) 1.8168985% .000 -35.679562% -23.720438% 
  Mix .2866667% 1.8168985% 1.000 -5.692895% 6.266229% 
  9:11 2.3266667% 1.8168985% .708 -3.652895% 8.306229% 
*  The mean difference is significant at the .05 level. 
 
Table 4.2: ANOVA test of values from MCF-7 Cells treated with 50µM CLA 
Percentage of viable cells after 24 hours treatment with 50µM CLA. Average of three 
experiments, cells incubated with Tryphan Blue. 
Key: Control – 100% ethanol (equivalent volume); LA – 50µM Linoleic Acid; Mix – 
50µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 50µM c9:t11 isomer alone; 
10:12 - 50µM t10:c12 isomer alone. 
 
 
 VII
Multiple Comparisons 
Dependent Variable: % viable cells  
Tukey HSD  
(I) 
Treatment 
(J) 
Treatment 
Mean Difference (I-
J) Std. Error Sig. 95% Confidence Interval 
        Lower Bound Upper Bound 
Con LA 5.4566667% 2.4409898% .242 -2.576831% 13.490165% 
  Mix 44.3700000%(*) 2.4409898% .000 36.336502% 52.403498% 
  9:11 39.6100000%(*) 2.4409898% .000 31.576502% 47.643498% 
  10:12 48.0733333%(*) 2.4409898% .000 40.039835% 56.106831% 
LA Con -5.4566667% 2.4409898% .242 -13.490165% 2.576831% 
  Mix 38.9133333%(*) 2.4409898% .000 30.879835% 46.946831% 
  9:11 34.1533333%(*) 2.4409898% .000 26.119835% 42.186831% 
  10:12 42.6166667%(*) 2.4409898% .000 34.583169% 50.650165% 
Mix Con -44.3700000%(*) 2.4409898% .000 -52.403498% -36.336502% 
  LA -38.9133333%(*) 2.4409898% .000 -46.946831% -30.879835% 
  9:11 -4.7600000% 2.4409898% .353 -12.793498% 3.273498% 
  10:12 3.7033333% 2.4409898% .575 -4.330165% 11.736831% 
9:11 Con -39.6100000%(*) 2.4409898% .000 -47.643498% -31.576502% 
  LA -34.1533333%(*) 2.4409898% .000 -42.186831% -26.119835% 
  Mix 4.7600000% 2.4409898% .353 -3.273498% 12.793498% 
  10:12 8.4633333%(*) 2.4409898% .038 .429835% 16.496831% 
10:12 Con -48.0733333%(*) 2.4409898% .000 -56.106831% -40.039835% 
  LA -42.6166667%(*) 2.4409898% .000 -50.650165% -34.583169% 
  Mix -3.7033333% 2.4409898% .575 -11.736831% 4.330165% 
  9:11 -8.4633333%(*) 2.4409898% .038 -16.496831% -.429835% 
*  The mean difference is significant at the .05 level. 
 
Table 4.3: ANOVA test of values from MD-MBA-231 Cells treated with 25µM CLA. 
Percentage of viable cells after 24 hours treatment with 25µM CLA. Average of three 
experiments, cells incubated with Tryphan Blue. 
Key: Control – 100% ethanol (equivalent volume); LA – 25µM Linoleic Acid; Mix – 
25µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 25µM c9:t11 isomer alone; 
10:12 - 25µM t10:c12 isomer alone. 
 
 
 VIII 
Multiple Comparisons 
Dependent Variable: % viable cells  
Tukey HSD  
(I) 
Treatment 
(J) 
Treatment 
Mean Difference 
(I-J) Std. Error Sig. 95% Confidence Interval 
              Lower Bound Upper Bound 
Con LA -5.0533333% 2.2376535% .235 -12.417635% 2.310968% 
  Mix 61.9166667%(*) 2.2376535% .000 54.552365% 69.280968% 
  9:11 56.8933333%(*) 2.2376535% .000 49.529032% 64.257635% 
  10:12 62.9700000%(*) 2.2376535% .000 55.605698% 70.334302% 
LA Con 5.0533333% 2.2376535% .235 -2.310968% 12.417635% 
  Mix 66.9700000%(*) 2.2376535% .000 59.605698% 74.334302% 
  9:11 61.9466667%(*) 2.2376535% .000 54.582365% 69.310968% 
  10:12 68.0233333%(*) 2.2376535% .000 60.659032% 75.387635% 
Mix Con -61.9166667%(*) 2.2376535% .000 -69.280968% -54.552365% 
  LA -66.9700000%(*) 2.2376535% .000 -74.334302% -59.605698% 
  9:11 -5.0233333% 2.2376535% .239 -12.387635% 2.340968% 
  10:12 1.0533333% 2.2376535% .988 -6.310968% 8.417635% 
9:11 Con -56.8933333%(*) 2.2376535% .000 -64.257635% -49.529032% 
  LA -61.9466667%(*) 2.2376535% .000 -69.310968% -54.582365% 
  Mix 5.0233333% 2.2376535% .239 -2.340968% 12.387635% 
  10:12 6.0766667% 2.2376535% .121 -1.287635% 13.440968% 
10:12 Con -62.9700000%(*) 2.2376535% .000 -70.334302% -55.605698% 
  LA -68.0233333%(*) 2.2376535% .000 -75.387635% -60.659032% 
  Mix -1.0533333% 2.2376535% .988 -8.417635% 6.310968% 
  9:11 -6.0766667% 2.2376535% .121 -13.440968% 1.287635% 
*  The mean difference is significant at the .05 level. 
 
Table 4.4: ANOVA test of values from MD-MBA-231 Cells treated with 50µM CLA. 
Percentage of viable cells after 24 hours treatment with 50µM CLA. Average of three 
experiments, cells incubated with Tryphan Blue. 
Key: Control – 100% ethanol (equivalent volume); LA – 50µM Linoleic Acid; Mix – 
50µM 50:50 mixture of the c9:t11 and t10:c12 isomers; 9:11 - 50µM c9:t11 isomer alone; 
10:12 - 50µM t10:c12 isomer alone. 
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